OTC + BC MACS Comprehensive Counselling Atlas

HIGH-DENSITY COUNSELLING GUIDE · 27 modules · Typical adult example regimens unless stated · Updated 25 October 2026

This comprehensive atlas combines the original nine GI/oral topics, nine MSK/infectious disease/dermatology chapters and nine newly added HEENT/respiratory/ocular chapters drawn from all uploaded lectures, including the dedicated Acne.pdf. Total 27 conditions/clinical modules. Regimens are condensed study examples; check the current Canadian monograph before counselling or prescribing.

Current BC MACS scope relevant here: Canker sores (topical), cold sores (antiviral category), GERD/dyspepsia (acid-reducing), localized musculoskeletal pain (NSAID category), uncomplicated UTI (antibiotics), acne and dermatitis (topical), onychomycosis (topical), allergic rhinitis (intranasal / oral antihistamine / ophthalmic categories) and conjunctivitis (ophthalmic). Sinusitis, pharyngitis, cough/cold, blepharitis, hordeolum/chalazion and dry eye are not distinct BC MACS diagnoses. Specialist medicines are included for pharmacotherapy context only. Students do not independently prescribe.

Dose rule: Typical example doses are for education, not patient-specific prescriptions. Check current Canadian DIN, actual brand formulation, pregnancy/breastfeeding status, renal/hepatic function, age/weight, drug interactions and prescriber authority. "Not specified" means the lecture did not provide a safe universal regimen.

TRIAGE FIRST: (1) identity, age/pregnancy, allergies and medications; (2) SCHOLAR-MACs (symptoms, characteristics, history, onset, location, aggravating/remitting, medicines, allergies, comorbidity); (3) red flags and differential; (4) non-drug + medicine choice; (5) exact dose, teaching, documented return precautions and date of reassessment. Emergency red flags: suspected ACS chest pain, GI bleeding, acute abdomen/obstruction, altered consciousness, significant dehydration/shock, ocular HSV.

ONE-GLANCE TRIAGE MATRIX

ComplaintBC statusRecognitionReferral triggerReview
Canker soresTopical MACSIntrabuccal round ulcers with pale centre>14 d, major, recurrent, systemic/immunosuppressed7 d
Cold soresOral/topical MACSTingling → grouped lip vesicles/crustEye involvement, systemic, immunosuppressed7 d
Dry mouthOTC; Rx outside MACSDry tongue, thick saliva, dysphagiaPersistent/unexplained, dental/systemic disease1 week
GasOTCBelching, flatulence, post-food bloatPain, altered bowel habits, persistent/new >401–2 wk
GERDAcid-reduction MACSRetrosternal burning/regurgitationChest pain, bleed, dysphagia, weight loss2–4 wk
DyspepsiaAcid-reduction MACSEpigastric pain, early satiety/fullnessAlarm symptoms; H. pylori evaluation2–4 wk
ConstipationOTC; Rx outside MACSHard/rare stool, strain, incompleteObstruction, bleeding, new >50, >2 wkDays; 2–4 wk
Diarrhea / TDOTC; ABx outside MACS≥3 loose stools/dayBlood, fever, dehydration, recent ABx24–48 h
Nausea/vomitingOTC; Rx outside MACSEmesis, retching; identify causeBlood, DKA/obstruction, dehydration, childHours–48 h
Localized MSK painNSAID MACSLocal soft tissue or peripheral joint painTrauma/deformity, unable bear weight, fever/hot joint3–7 d
Uncomplicated cystitisAntibiotic MACSDysuria, frequency, urgency; no systemic sxFever/flank pain, pregnancy, complex illness48 h
Head liceOTC onlyLive moving lice, scalp itchScalp infection, failure after correct courses7–10 d
ScabiesOTC/clinicianNocturnal itch, burrows, household casesCrusted/immunocompromised, infants, atypical1–4 wk
RosaceaRx external MACSCentrofacial erythema, no comedonesEye pain/vision changes, rhinophyma8–12 wk
OnychomycosisTopical MACSDiscoloured, thick, crumbly nailMatrix or extensive disease, melanoma risk3–12 mo
Atopic dermatitisTopical MACSItchy dry relapsing eczemaInfection/herpeticum, severe widespread5–14 d
Contact dermatitisTopical MACSExposure pattern, eczematous rashSevere bullae, >20% BSA, sensitive sites5–7 d
Acne vulgarisTopical MACSComedones ± papules/pustulesScarring, nodules, severe distress8–12 wk
SinusitisOTC; antibiotics other prescriberPODS + viral <10 d vs bacterial ≥10 d/double sickeningEye swelling, vision loss, severe headache/neck stiffness48–72 h
Allergic rhinitisBC MACS intranasal / H1 / ophthalmicNasal itch/sneeze, clear discharge, allergic triggerUnilateral bleeding, refractory, severe breathing/eye symptoms3–7 d
PharyngitisOTC; antibiotics other prescriberViral cough/coryza vs GAS fever, exudate, no coughStridor, drooling, trismus, unilateral swelling48–72 h
Common coldOTC onlySore throat → rhinorrhea → cough; viralBreathing difficulty, fever >3 d, worsening48–72 h
CoughOTC onlyDry vs productive; postviral possibleDyspnea, hemoptysis, COPD flare, >3 wk48–72 h
ConjunctivitisBC MACS ophthalmicPurulent bacterial; watery viral; itch allergicContact lens painful red eye, photophobia, vision loss24–48 h
BlepharitisOTC lid care; Rx other prescriberChronic bilateral crusts vs oily/foamy tearsVisual change, pain, persistent despite care1–2 wk
Hordeolum/chalazionOTC careTender acute stye vs slow sterile lumpSpreading eyelid infection, visual change2–7 d
Dry eyeOTC lubricants; Rx outside MACSGritty burning/fluctuating blur, paradoxical tearsPain, photophobia, contact lens red eye3–5 d

01 | Aphthous ulcers / canker sores

BC MACS: topical Schedule I drugs for eligible minor oral ulcersLecture basis: GI 14 slides 5–23

Risk factors / causes

Female sex; family history; age <40; immune dysfunction; deficient B1/B2/B6/B12, iron, folate or zinc; stress; oral trauma; hormonal change; recent smoking cessation; SLS toothpaste; certain foods/additives; ACEi, beta-blockers, NSAIDs, immunosuppressants.

Clinical presentation

Minor (70–95%): 1–5 painful round/oval ulcers <1 cm with pale/yellow fibrin centre and erythematous halo, NON-keratinized inner cheeks/lips, underside of tongue, floor/soft palate; 7–14 d, no scar. Major: >1 cm, deep, 1–10, weeks–months and scars. Herpetiform: ≥10 pinpoint 1–3-mm lesions, may coalesce; NOT HSV. Noncontagious, no external lip vesicles.

When to REFER / exclude self-care

Major/herpetiform lesions; >14 d or scarring; marked pain limiting hydration/intake; frequent ≥6–12 episodes/year; first occurrence >30; immunosuppression/HIV/IBD; fever or extraoral/genital/ocular lesions; hard or indurated suspicious lesion; unusual hard-palate/gingival lesions; suspected drug reaction or systemic disease (Behçet, Crohn, malignancy), uncertain diagnosis.

Complications + goals

Complications: Poor eating/dehydration, rarely weight loss; secondary infection; underlying systemic disease missed.

Goals: Comfort in 1–2 d; normal oral intake; healing by 14 d; avoid recurrence and infection.

First-line counselling / non-drug treatment: Soft toothbrush, alcohol-free mouth rinse, consider SLS-free paste; saltwater rinse ½–1 tsp salt/cup warm water; avoid sharp, citrus, salty, acidic and spicy foods; correct dentures/braces; water and oral hygiene.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Acetaminophen [OTC] | 325/500-mg oral tabs325–650 mg q4–6h or 500–1,000 mg q6h PRN pain for several days; prudent self-care max 3 g/day adult (lower with liver disease/low weight).Severe liver disease; duplicate combination acetaminophen; chronic heavy alcohol.Nausea uncommon; dose-dependent hepatotoxicity with overdose; alcohol/warfarin (regular high use).Pain at 24–48 h; total acetaminophen from all products; stop as ulcer heals.
Benzocaine [OTC] | multiple gels, commonly 10–20%Dry ulcer; thin application up to 4 times/day before meals/bedtime, up to 7 d; no food/drink ~30 min. Exact formulation label governs.Under 2 years; prior methemoglobinemia, benzocaine/ester-anesthetic allergy; avoid large or damaged area.Stinging, contact allergy; rare life-threatening methemoglobinemia (blue/gray skin, dyspnea)—urgent care; few systemic DDIs.Immediate temporary relief (~20–45 min); stop for irritation/cyanosis.
Lidocaine viscous/topical [formulation-dependent] | 2%Local small-amount application as specifically directed by product/prescriber; dose not supplied in lecture—verify maximum by age/weight.Young children, swallowing impairment; excess dosing; hepatic disease or cardiac conduction issues.Numbness, burns/bites, aspiration and systemic toxicity if swallowed; antiarrhythmics add toxicity.Swallowing and oral injury; do not eat while numb.
Hydroxypropylcellulose (Zilactin) / carboxymethylcellulose (Orabase) [OTC protective paste]Dry area then dab a small coating at bedtime and as needed; avoid food/drink for 30 min; use until healing.Product allergy; check age-specific label.Sticky sensation, local irritation; minimal DDIs.Comfort and ability to eat; worsening irritation.
Triamcinolone acetonide 0.1% dental paste (Oracort) [MACS Rx]Dry surface; press/dab small amount after meals 2–3 times/day and at bedtime; begin early; generally ≤7 d per lecture. Do NOT rub in.Suspected herpes, thrush, other oral infection or untreated bacterial infection; corticosteroid hypersensitivity.Local irritation, candidiasis/secondary infection; systemic effects unlikely with small area; other immunosuppressants increase infection concern.Pain 1–2 d, smaller ulcer by day 7, fully healed ≤14 d; examine for thrush, refer if no improvement by 7 d.
Vitamin B12 [OTC nutritional supplement] | sublingual 1,000 micrograms1,000 micrograms SL once daily for ≥4 months as a trial for frequent recurrent aphthae; NOT acute analgesia.Investigate significant deficiency or underlying malabsorption; not a substitute for diagnostic workup.Generally tolerated; clinically important interactions uncommon.Episode frequency over 4–6 months; check B12/iron/folate if deficiency suspected.
FOLLOW-UP TIMELINE: Contact/check at ~7 d; pain within 1–2 d, lesions gone within 14 d. Refer for persistence, enlarging lesion, infection, impaired intake or recurrence; discontinue topical agents upon healing.

02 | Herpes labialis / cold sores

BC MACS: topical or oral Schedule I antivirals; OTC supportive treatmentsLecture basis: GI 14 slides 24–55

Risk factors / causes

HSV-1 usually (sometimes HSV-2). Previous exposure, close contact and shedding; triggers: UV light, fever/illness, trauma, stress, menstrual hormonal changes, immunosuppression. Recurrent >6/y suggests need to reassess.

Clinical presentation

Prodrome tingling/burning/itching then clustered papules → vesicles on lip/vermilion/perioral skin → ulcer/crust in ~7–14 d. May sting. Primary infection may cause fever, diffuse gingivostomatitis, painful nodes, poor intake. Contagious from prodrome until completely healed.

When to REFER / exclude self-care

Age <12 per lecture referral rule; immunocompromised; possible ocular involvement (RED EYE, pain, photophobia: urgent same-day); extensive intraoral/pharyngeal disease; fever/systemic illness, dehydration; spreading beyond lip, atypical/uncertain diagnosis; severe purulence/bleeding; >14 d; not improving by 7 d; >6 recurrences/y.

Complications + goals

Complications: HSV keratitis, eczema herpeticum, secondary bacterial infection, dehydration in primary gingivostomatitis, spread to others.

Goals: Minimize pain and outbreak by ~0.5–2 d if treated VERY early; prevent spread; consider suppression only for frequent episodes.

First-line counselling / non-drug treatment: At prodrome avoid kissing/oral sex, sharing lip balm/utensils/towels; wash hands after touching, avoid eye contact. Mild soap/cool compress and petrolatum barrier; UV SPF≥30 lip protection; avoid irritating foods. Antivirals most effective if begun within hours, ideally prodrome or first 48 h.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Docosanol 10% cream (Abreva) [OTC]Apply thin layer 5 times/day ~q3–4h beginning within 12 h of prodrome; typically up to healing, 5–10 d (check package maximum).Product hypersensitivity; evidence limited later in established crusts.Local stinging/burning, headache; systemic DDIs unlikely.Lesion pain/size each day; expect modest time reduction only.
Acyclovir 5% cream (Zovirax) [MACS Rx]Apply 5 times/day at first prodrome, ideally within 1 h, for 4 d. Cream preferred to ointment in lecture.Known allergy; avoid eyes/intraoral use unless product specifically intended.Local rash/irritation; minimal systemic DDIs.Healing/pain by days 3–7; refer if worsening or >14 d.
Acyclovir 5% + hydrocortisone 1% cream [MACS Rx, if available]Apply 5 times/day for 5 d, starting immediately at prodrome; verify Canadian availability.Avoid bacterial/fungal facial skin infection or eye; uncertain lesion diagnosis.Local irritation, theoretical steroid-associated infection; minimal DDIs.Resolution and appearance of new vesicles, 3–7 d.
Acyclovir PO [MACS Rx] | 200-/400-mg tabletsRECURRENT: 400 mg PO 5 times/day for 5 d. PRIMARY moderate–severe: 200 mg 5 times/day OR 400 mg TID for 7 d (lecture regimens).Renal impairment/dehydration—adjust; allergy; verify need for systemic treatment.Headache, nausea; renal crystal nephropathy/neurotoxicity at excessive dose/renal impairment; nephrotoxins (NSAIDs) increase risk.Ensure hydration; check renal function where indicated; symptoms days 3–7.
Valacyclovir PO [MACS Rx] | 500-mg, 1-g tabletsRECURRENT: 2 g PO BID for ONE day (two doses 12 h apart; take immediately). PRIMARY: 1 g PO BID x 7 d (lecture).Renal dose adjustment, dehydration, severe immunosuppression outside simple MACS scenario.Headache, nausea; rare renal/neurotoxicity; caution concomitant nephrotoxins.Lesion/healing within 7–14 d; check renal dosing.
Famciclovir PO [MACS Rx] | 250-/500-mg tabletsRECURRENT: 1,500 mg PO once OR 750 mg PO BID x 1 d. PRIMARY: 250 mg TID OR 500 mg BID x 7 d (lecture).Renal impairment requires adjustment; pregnancy/lactation data more limited.Headache, nausea, dizziness; possible nephrotoxic drug coexposure concern.Pain and days to resolution, check renal function if indicated.
Topical benzocaine/lidocaine/pramoxine [OTC symptom relief]Apply small amount to intact surrounding skin per specific label PRN for brief pain relief; strengths/intervals vary by product.Local anesthetic allergy; avoid mouth/eyes; benzocaine methemoglobinemia caution.Burning, sensitization; excessive dosing toxicity; few systemic interactions.Comfort; any rash/systemic effects.
Petrolatum / zinc oxide / cocoa-butter barrier [OTC]Apply thin layer PRN to prevent cracking until crust resolves.Topical hypersensitivity.Rare irritation; no material DDIs.Cracking, secondary infection.
Zinc sulfate (Lipactin) / propolis 3% / lysine [NHP]Zinc topical q2h x 5 d early; propolis topical 4–6 times/day; lysine prevention 500–1,000 mg PO QID per slide (low-quality evidence).Avoid propolis with bee/pollen allergy or asthma; oral lysine caution renal/hepatic impairment and pregnancy.Contact reaction, uncertain efficacy; lysine long-term data limited.Do not replace antiviral; refer if course atypical.
Acyclovir/valacyclovir chronic suppression [clinician-directed—not routine MACS episodic visit]Lecture preventive examples: acyclovir 200 mg QID or 400 mg BID x 4 months; valacyclovir 500 mg daily x 4 months; reassess need.Frequent recurrence should prompt clinician assessment; renal adjustment.Headache/nausea, possible nephrotoxicity; monitor renal risk.Recurrence count over 4 months; reassess stopping/long-term plan.
FOLLOW-UP TIMELINE: Follow up at day 7; expected episodic healing day 7–14. Refer if new ocular/systemic symptoms, expansion, poor response at 7 d, or lesions still present >14 d. Stop contact transmission precautions only after complete healing.
High-yield counselling / differential: Primary severe oral gingivostomatitis requires individualized assessment; do not treat an atypical primary severe case as routine minor recurrent labialis. Never use triamcinolone dental paste on herpes.

03 | Xerostomia / dry mouth

OTC counselling; systemic sialagogues are NOT a BC MACS indicationLecture basis: GI 14 slides 56–75

Risk factors / causes

Older age/polypharmacy, anticholinergic burden (1st-gen antihistamines, oxybutynin, scopolamine), TCAs, paroxetine/venlafaxine/bupropion, antipsychotics, opioids, diuretics; diabetes, hypothyroidism, Sjögren, CKD/dehydration, HIV; head-neck radiation; tobacco, caffeine, alcohol, cannabis; mouth breathing or CPAP.

Clinical presentation

Dry/sticky mouth, thick stringy saliva, thirst, dysgeusia, halitosis, dysphagia for dry food, speaking difficulty; dry fissured lips/tongue, angular cheilitis, increased caries; dry eyes suggest Sjögren.

When to REFER / exclude self-care

Persistent/unexplained symptoms; severe dysphagia, weight loss, dental infection/thrush; dry eyes/systemic autoimmune symptoms; head-neck radiotherapy; medication changes needed; swelling/mass, oral ulcer, dehydration. Refer dentist for new caries risk.

Complications + goals

Complications: Dental caries/periodontitis, oral candidiasis, impaired food intake/nutrition, sleep disturbance, speech/swallowing difficulty.

Goals: Increase comfort/salivary function, prevent dental disease/candidiasis; address drug or disease cause.

First-line counselling / non-drug treatment: Water sips/ice chips; sugar-free xylitol gum/lozenges if glands work, humidifier, lip balm; meticulous fluoride dental care, dental review, alcohol-free mouthwash; avoid alcohol mouthrinses, tobacco, acidic/sugary foods, excessive caffeine. Ask prescriber about anticholinergic deprescribing/dose adjustments (never self-stop).
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Artificial saliva (Biotène, Moi-Stir, Mouth-Kote, Oralbalance) [OTC] | spray/gel/rinseApply as label directs, especially before meals/bed and PRN; often lasts ~1 h. Formulations vary (carboxymethylcellulose, enzymes, mucopolysaccharides).Product ingredients allergies; check sugar/acid composition and dental risk.Usually local irritation or unpleasant taste; negligible interactions.Comfort after each use; oral mucosa/caries; review at 1 week.
Sugar-free xylitol / sorbitol / mannitol gum or lozenges [OTC]Chew/suck frequently PRN while awake if salivary glands functional; strength varies widely by brand.Choking risk, chewing problems; caution sorbitol in diarrhea.Polyol-related gas/bloating/diarrhea; minimal drug interactions.Saliva benefit, GI tolerance, oral hygiene.
Citric acid 5% glycerin / lemon-glycerin swabs [OTC]Use PRN per product; not preferred for repeated use if dental enamel vulnerable.Erosion/caries, mucosal ulceration; sensitive mouth.Stinging, enamel risk from acid; no significant DDIs.Oral irritation, tooth sensitivity.
Anetholtrithione 25 mg tablet (Sialor) [non-MACS product; access/availability check]25 mg PO TID before meals per lecture; duration not specified—reassess after 1–2 weeks.Suspected bile duct obstruction or hepatic disease requires prescriber review; verify marketed status.Abdominal discomfort, flatulence; long-term safety uncertain; DDIs not well characterized.Symptom response, GI intolerance.
Pilocarpine (Salagen) 5-mg oral [Rx, NOT MACS]5 mg PO TID–QID; lecture max 30 mg/day. Specialist/prescriber for Sjögren or post-radiotherapy xerostomia.Uncontrolled asthma, acute iritis/narrow-angle glaucoma, significant cardiopulmonary disease; GI obstructive disorders; caution older adults.Sweating, nausea, urinary frequency, lacrimation, dizziness, diarrhea, brady/tachyarrhythmia; anticholinergics oppose effect, beta blockers may add bradycardia.Saliva/comfort and sweating/BP/HR in first days–weeks; dental surveillance.
FOLLOW-UP TIMELINE: Follow up in 1 week for salivary substitute response; longer interval for salivary stimulant under prescriber. Monitor sores, candidiasis, weight/intake, sleep, and dental caries. Persistent symptoms → dentist/clinician medication review.
High-yield counselling / differential: NOTE: “Prescription treatment exists” ≠ a BC minor-ailment prescribing indication. Xerostomia does not appear in the 21 MACS conditions.

04 | Bloating, belching and intestinal gas

OTC only (no gas-specific MACS indication)Lecture basis: GI 09 slides 4–17

Risk factors / causes

Aerophagia: eating rapidly, chewing gum, smoking, carbonated beverages; fermentable FODMAPs/oligosaccharides, lactose maldigestion, high-fibre diet; constipation/IBS/celiac; some drugs changing microbiome, digestion or GI motility.

Clinical presentation

Belching, passing flatus, episodic bloating, distention and mild cramping linked to meals. Lactose: gas, cramping, diarrhea after dairy; oligosaccharides: symptoms after beans, legumes, onions or some grains.

When to REFER / exclude self-care

Severe/persistent/frequent new symptoms, sudden altered bowel habits, new onset >40, weight loss, fever, vomiting, bleeding, severe focal pain, persistent diarrhea/constipation, signs of obstruction, known GI disease.

Complications + goals

Complications: Most transient; if persistent may signify GI pathology; dehydration or nutritional restriction from unnecessary avoidance.

Goals: Reduce meal-related discomfort and bloating, identify dietary trigger, preserve adequate diet.

First-line counselling / non-drug treatment: Slow down eating, chew well, smaller meals; avoid gum/smoking/fizzy drinks and excess high-FODMAP foods when identified; avoid lying flat 2–3 h after eating; selective lactose reduction with fortified alternatives and calcium/vitamin D adequacy.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Simethicone [OTC] | 80-/125-/180-mg forms80–160 mg PO after meals/at bedtime up to QID PRN per lecture; follow formulation label; short trial ~1–2 weeks.Hypersensitivity; assess for obstruction instead of masking severe distention.Minimal absorption, adverse effects/DDIs negligible; evidence for isolated intestinal gas weak.Bloating/distention after 3–7 d; stop if no benefit.
Lactase enzyme [OTC] | 9,000 FCC unitsTake 9,000 FCC units with first bite of lactose-containing food or immediately before; repeat with separate meals (product-specific).Milk protein allergy is NOT lactose intolerance; cannot prevent allergic reactions.Minimal adverse effects/DDIs; high lactose loads can still cause symptoms.Symptoms after dairy exposure over 1–2 weeks; diet tolerance.
Alpha-galactosidase [OTC] | 150–450 GalUTake 150–450 GalU with FIRST bite of gas-forming food (beans, vegetables, whole grains); each triggering meal.Rare enzyme allergy; product source ingredients (e.g., Aspergillus) and galactosemia considerations.Possible hypersensitivity; efficacy variable; minimal known DDIs.Bloating/flatulence after trigger foods over 1–2 weeks.
Bismuth subsalicylate [OTC] | 262-mg tablet524 mg PO every 30–60 min PRN, maximum 8 DOSES = 16 ×262-mg tabs per 24 h; short term ≤2 d for acute GI symptoms. Less useful for uncomplicated gas.Salicylate allergy, active bleeding/ulcer, anticoagulants, pregnancy, children/teens with viral illness; renal disease.Black tongue/stool, nausea; bleeding (warfarin, DOACs, antiplatelets, NSAIDs); interaction with tetracyclines.GI symptoms and black stools vs genuine bleeding; stop if no response.
Probiotics [OTC] | strain/product variableNo universal evidence-based gas dose or duration; use manufacturer regimen only if individual indication established.Significant immunocompromise/central lines/high-risk medically ill patients—avoid without clinician input.Transient gas; very rare invasive infection; no routine DDIs.Document exact strain, measure response at 1–2 weeks.
FOLLOW-UP TIMELINE: Recheck at 1–2 weeks; if benefit after week 1 may continue another week. Persistent gas despite correctly targeted meal-based enzyme or dietary adjustment → investigate/refer.
High-yield counselling / differential: Simethicone changes bubble surface tension; it does NOT reduce gas production. Bismuth may reduce sulfide-related odor but is not first-line for routine flatus.

05 | GERD / uncomplicated heartburn

BC MACS: gastric acid-reducing Schedule I medicinesLecture basis: GI 11 slides 6–53

Risk factors / causes

Obesity, pregnancy, smoking, hiatal hernia, older age, stress; large/fatty meals, caffeine, alcohol, chocolate, peppermint, acid foods. Drugs: CCB, nitrates, anticholinergics, benzodiazepines, β2-agonists, GLP-1RA, opioids; pill esophagitis from bisphosphonates, iron, KCl, doxycycline, NSAIDs.

Clinical presentation

Characteristic RETROSTERNAL burning + acid regurgitation, worsened after meals/lying/bending, +/- water brash, belching, cough/hoarseness. Infrequent <2 days/week; frequent ≥2. Severe disrupts ADLs or sleep.

When to REFER / exclude self-care

EMERGENCY for suspected cardiac chest pain. Other: dysphagia/odynophagia; GI bleed/melena/anemia; weight loss; mass; recurrent vomiting; cancer family history; >50 new/worsening; <18 under lecture PPMAC criteria; nocturnal/severe, respiratory symptoms, uncertain diagnosis; failed adequate PPI, relapse <90 days.

Complications + goals

Complications: Erosive esophagitis, peptic stricture, Barrett esophagus, esophageal cancer, dental erosion; sleep impairment.

Goals: Relief 2–7 d, symptom remission during 4–8 weeks; heal esophagitis where present; lowest effective maintenance therapy if objectively indicated.

First-line counselling / non-drug treatment: Lose weight if indicated; individualized food diary rather than blanket elimination; reduce large/late meals, no meals 2–3 h before bed; elevate head of bed for nocturnal symptoms, avoid tobacco, trigger beverages, tight clothes; review offending medicines.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Calcium carbonate (Tums) [OTC] | commonly 500/750/1,000-mg chewablesProduct-dependent: e.g. 500–1,000 mg calcium carbonate chewed PRN for infrequent symptoms; do not exceed label/day; short-term, often a few days.Hypercalcemia, nephrolithiasis, excessive calcium supplementation, severe renal disease; distinguish elemental Ca.Constipation, belching; milk-alkali syndrome with chronic large doses. Chelates levothyroxine, tetracyclines, quinolones, iron, bisphosphonates: separate 2 h before or 4–6 h after as appropriate.Relief within minutes; frequency of use, constipation; avoid daily reliance.
Magnesium hydroxide/aluminum hydroxide antacids [OTC] | liquid/tablet variesPer product label PRN after meals/bed; doses depend on formulation; lecture does not provide a universal mg dose.Avoid Mg or Al in renal impairment; Al causes hypophosphatemia prolonged exposure; elderly caution.Mg diarrhea; Al constipation, belching; same chelation/absorption DDIs as other antacids.Symptoms within minutes, diarrhea/constipation and renal risk.
Sodium bicarbonate / ASA-containing effervescent antacid (e.g. Alka-Seltzer) [OTC]Formulation-specific label PRN; not preferred for routine GERD.Heart failure, HTN, edema, cirrhosis, CKD, pregnancy due sodium; ASA-containing types: anticoagulation, GI bleed, aspirin allergy.Bloating/metabolic alkalosis, sodium load, GI bleeding; NSAID/anticoagulant interactions.Fluid status and bleeding; recommend alternative for most.
Alginate + antacid (e.g. Gaviscon) [OTC] | strengths vary by Canadian productChew/tablet or liquid after meals and at bedtime per exact label; useful for meal-triggered symptoms; short PRN course.Sodium-content caution in HF/CKD; antacid mineral warnings depend on formulation.Minor bloating, calcium/magnesium DDIs if included; separate from other drugs.Postprandial symptom improvement shortly after administration.
Famotidine [OTC/Rx] | 10-,20-,40-mg tabsOTC 10–20 mg PO once or BID PRN for symptoms/anticipated trigger. Rx 20–40 mg BID for selected cases. PPMAC infrequent: trial on demand or BID x 2 weeks; reassess.Renal impairment: reduce dose/extend interval; allergy.Headache, dizziness, constipation/diarrhea; acid-dependent drug absorption (azole antifungals, iron), possible levothyroxine effect; H2RA tolerance in 2–6 weeks.Relief hours after dose; symptom days 2–7, renal risk, need for regular use.
Ranitidine / nizatidine / cimetidine [historical/alternative H2RA]Lecture: ranitidine OTC 75–150 mg daily, Rx 150 mg BID or 300 mg daily; nizatidine 150 mg BID; cimetidine 800 mg daily or 600 mg BID or 300 mg QID. Verify current Canadian marketed status before use; FAMOTIDINE usually preferred.All require renal consideration; cimetidine additionally liver disease and interacting medications; ranitidine has NDMA testing history.Cimetidine inhibits multiple CYP enzymes (warfarin, phenytoin, theophylline etc), antiandrogenic effects; headache/GI effects.Reassess quickly; not automatically substitute old slide brands.
Omeprazole [OTC/Rx] | 20-mg capsules20 mg PO daily 30–60 min before breakfast x 4 weeks, extend x 4 more weeks only if appropriate. Not rapid PRN.Alarm symptoms/possible malignancy; severe liver disease; assess high-risk ongoing therapy.Headache, diarrhea, constipation; CYP2C19 inhibits clopidogrel activation; may raise phenytoin/warfarin/citalopram exposure; reduces acid-dependent absorption (azole antifungals, iron, levothyroxine).Reassess 2–4 weeks, relief days 2–7; long-term need and Mg/B12/renal issues if maintained.
Esomeprazole [OTC/Rx] | 20/40 mg20 or 40 mg PO daily 30–60 min before meal x 4–8 weeks depending case.As for PPI; consider contraindications to acid suppression.As PPI; same clinically relevant clopidogrel CYP2C19 interaction as omeprazole.Symptom response 2–4 weeks; deprescribe when resolved.
Pantoprazole (Na or Mg) [MACS Rx] | 40 mg40 mg PO daily 30–60 min before a meal x 4 weeks (option continuation to 8 weeks depending severity); can be selected when CYP2C19 interaction concern.As for PPI; watch multiple-drug regimens.Headache/diarrhea, rare AIN and hypomagnesemia long term; acid-dependent absorption DDIs.Response 2–4 weeks; reassess need at end of course.
Lansoprazole [MACS Rx] | 30 mg30 mg PO daily 30–60 min before breakfast x 4–8 weeks.PPI contraindications; caution in severe liver disease.Class GI/CNS ADRs; acid-suppression DDIs.Relief in days, reassess 2–4 weeks.
Rabeprazole [MACS Rx] | 20 mg20 mg PO daily before meal x 4–8 weeks.PPI cautions.GI/CNS effects; acid-suppression DDIs.Response 2–4 weeks.
Dexlansoprazole [MACS Rx when appropriate] | 30/60 mg30 or 60 mg PO daily x 4–8 weeks depending presentation and product monograph; dual-release, less meal-dependent.PPI cautions, coverage restrictions.Class ADRs/DDIs, possibly reduced acid-dependent drug absorption.Response at 2–4 weeks.
Domperidone / metoclopramide [Rx specialist-directed, NOT gastric acid-reducing]Not routine GERD PPMAC drugs. GI motility disorders only; dosing individualized by prescriber (not specified in GERD lecture).QT/arrhythmias with domperidone; EPS/tardive dyskinesia & obstruction with metoclopramide.Domperidone interactions with QT prolongers/CYP3A4 inhibitors; metoclopramide with antipsychotics/CNS sedatives.Clinical indication and cardiac/neurological monitoring with prescriber.
FOLLOW-UP TIMELINE: Infrequent mild: antacid/alginate or H2RA PRN for ~2 weeks; step up if persistent. Frequent (≥2 d/week) or moderate: standard PPI daily x 4 weeks, reassess at 2–4 weeks; continuation to ~8 weeks if responding. Any failure, severe cases, red flags or relapse <90 days -> refer. Long-term PPI: annually verify indication, lowest effective dose; monitor C. difficile, AIN, Mg/B12 when risk based.
High-yield counselling / differential: PPIs are not instantaneous PRN agents. H2RAs develop tachyphylaxis; antacids chelate multiple oral drugs. All acid suppression can change absorption of medicines requiring acidic pH. Slide includes ranitidine; some Canadian products are marketed under batch testing and others cancelled—check current DIN/product status.

06 | Dyspepsia / epigastric pain

BC MACS: gastric acid-reducing Schedule I medicines ONLY in suitable presentationsLecture basis: GI 11 slides 54–69

Risk factors / causes

Female sex; H. pylori infection; NSAIDs, ASA, steroids, iron, bisphosphonates, metformin, antibiotics, KCl; smoking, alcohol, caffeine, spicy/acidic foods. Differential includes ulcer, GERD, gastroparesis, biliary disease, celiac, malignancy, angina.

Clinical presentation

Epigastric pain/burning, postprandial fullness or early satiety, sometimes nausea/belching/bloating. Functional dyspepsia is diagnosis after exclusion of structural disease (Rome pattern ≥3 months, started ≥6 months ago). Unlike GERD, heartburn/regurgitation is not predominant.

When to REFER / exclude self-care

Same alarm features as GERD: GI bleeding, anemia, weight loss, persistent vomiting, dysphagia, mass, family cancer history, suspected cardiac pain; onset >50 new/worsening, younger with high risk; unexplained persistent dyspepsia needing H. pylori testing/endoscopy; incomplete response at 2–4 weeks.

Complications + goals

Complications: Peptic ulcer complications if missed (bleeding/perforation), malnutrition/quality of life; misdiagnosed cancer or ischemia.

Goals: Reduce epigastric symptoms/fullness; treat H. pylori when identified, avoid offending medicines, minimize long-term acid suppression.

First-line counselling / non-drug treatment: Smaller regular meals, avoid personally reproducible triggers and NSAIDs when possible; manage stress, tobacco/alcohol; clarify whether reflux predominant, medicine-induced, or associated with lactose intolerance.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
PPI [MACS Rx] | usual once-daily optionsOmeprazole 20 mg; esomeprazole 20–40 mg; lansoprazole 30 mg; pantoprazole 40 mg; rabeprazole 20 mg; dexlansoprazole 30–60 mg PO daily, usually before breakfast (except dexlansoprazole). Trial 4–8 weeks; refer if no response by 2–4 weeks.All GERD alarm features. Assess H. pylori test need before empiric PPI as PPI can affect test results; prolonged use should be justified.Headache, diarrhea/constipation, rare AIN; omeprazole/esomeprazole–clopidogrel interaction; absorption of pH-dependent drugs.Record pain/fullness 0–10, intake and response at 2–4 weeks; taper/stop if resolved.
Famotidine [OTC/Rx] | 10/20/40 mg10–20 mg PO up to BID (OTC) or prescribed 20–40 mg BID; lecture second-line option x 4–8 weeks.Renal impairment, alarm signs; less effective than PPI.Headache, dizziness, GI symptoms; reduced absorption of pH-dependent drugs; tachyphylaxis.Symptom relief and frequency, renal function if needed.
Antacids/alginate [OTC]Per formulation PRN; useful for short-term symptom relief when reflux overlaps; not proven functional dyspepsia treatment.Renal impairment with Al/Mg, hypercalcemia with high-dose Ca, drug chelation.Diarrhea/constipation, chelation DDIs; separate medications.Prompt symptom relief only; reassess ongoing need.
TCAs (amitriptyline/imipramine) or prokinetics [clinician-directed Rx, NOT MACS for dyspepsia]Discussed for refractory functional dyspepsia after PPI; lecture does not specify dose. Requires physician-led diagnostic plan.TCA cardiac/anticholinergic risk; prokinetic EPS/QT and obstruction risks.Dry mouth, constipation, sedation, cardiac effects; many CNS and QT interactions.Specialist assessment for refractory symptoms and monitoring.
FOLLOW-UP TIMELINE: PPI trial x 4–8 weeks, review at 2–4 weeks. If persists, refer for H. pylori testing or other diagnosis; after response stop/taper PPI when safe and review again if recurrent.
High-yield counselling / differential: GERD = retrosternal heartburn/regurgitation; dyspepsia = EPIGASTRIC pain, post-meal fullness and early satiety. Dyspepsia often merits H. pylori evaluation; PPMAC is not permission to initiate H. pylori eradication antibiotics.

07 | Constipation: acute, chronic, opioid-induced

OTC management; newer laxatives and PAMORAs are clinician-prescribed, NOT a constipation MACS indicationLecture basis: GI 05 slides 8–53

Risk factors / causes

Female sex, pregnancy, older age, low fluid/fibre, immobility, changing routine. Drugs: opioids, anticholinergics, TCAs, antipsychotics, CCBs, diuretics, iron, Ca/Al, ondansetron, loperamide, cholestyramine. Diseases: hypothyroidism, diabetes, CKD, Parkinson, MS, IBS-C, obstruction, pelvic-floor dyssynergia.

Clinical presentation

Hard/lumpy stools (Bristol 1–2), straining, incomplete evacuation, bloating/discomfort and infrequent BMs. Chronic: ≥2 symptoms for >25% of BMs in last ≥3 months, onset ≥6 months before; <3 spontaneous BMs/week may be one criterion. OIC: new/worse symptoms after starting/escalating opioid; tolerance to constipation seldom develops.

When to REFER / exclude self-care

SEVERE abdominal pain/distention, vomiting, no flatus (possible obstruction); blood/black stools, rectal mass/tenesmus, fever, anemia, weight loss, family IBD/CRC, abrupt change, new onset ≥50; >2 weeks persistent constipation or no BM >7 d despite laxatives; in infants: neonatal onset, failure to thrive, severe distention, fever/blood. Do not give bulk or stimulants with suspected obstruction.

Complications + goals

Complications: Hemorrhoids, anal fissure, impaction/overflow incontinence, prolapse, stercoral ulcer, ileus/intestinal obstruction.

Goals: Soft non-forced comfortable BM at individualized frequency, usually ≥3/week; acute relief within 1–3 d; prevent complications and use lowest necessary laxatives.

First-line counselling / non-drug treatment: Gradual soluble fibre increase ~5 g/week to 20–30 g/day total, if no obstruction/dyssynergia and able to hydrate; adequate fluid (~1.5 L/day if appropriate), exercise and regular post-meal toilet routine, footstool; review medications, thyroid/metabolic contributors. Suspected impaction requires exam/management rather than fibre loading.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Psyllium (Metamucil) [OTC] | sachets; typical 3.4 g/dose3.4–6.8 g PO once daily up to TID; maximum ~30 g/day per lecture. Full glass ≥250 mL every dose. Titrate weekly. Onset 12–72 h.Dysphagia, esophageal stricture, impaction, obstruction, dehydration/fluid restriction, pelvic floor dyssynergia.Bloating/gas; may delay other drug absorption (physical trapping): space ~2 h from other oral drugs.Stool softness and bloating at 3–7 d, BM pattern at 2–4 weeks.
Methylcellulose (Citrucel) / calcium polycarbophil [OTC]Methylcellulose 2 caplets once daily to QID (strength label-dependent); polycarbophil 2 ×625-mg caplets once daily to QID, max 8/day; onset 12–72 h.Same swallowing/obstruction/fluid restrictions as bulk fibre.Bloating; separate other oral drugs by ~2 h.Hydration and stool consistency over days–weeks.
Inulin fibre gummies [OTC]4 g PO BID per lecture; confirm actual product strength and maximum.Not with obstruction or inadequate fluid; high FODMAP sensitivity.Gas/bloating; few systemic DDIs.Tolerance after 1 week.
Polyethylene glycol PEG 3350 [OTC] | 17-g sachet/cap17–34 g PO dissolved in ~250 mL fluid once daily; titrate to effect. Onset 48–96 h. Can maintain for chronic constipation when appropriate.Suspected bowel obstruction; severe unexplained abdominal pain; dehydration requiring other care.Diarrhea, cramping, bloating; few drug interactions in routine doses; lecture suggests 2-h separation in osmotic group—more relevant for some drugs/rapid GI transit than direct binding.Stool form/BMs by days 3–5, fluid intake; excessive diarrhea/electrolyte symptoms with overuse.
Lactulose [OTC/Rx depending formulation] | commonly 667 mg/mL syrup15–30 mL PO once daily to TID; lecture max 90 mL/day. Onset 24–48 h. Sweet syrup can dilute.Bowel obstruction; galactose restriction/galactosemia (specific product); diabetes usually acceptable but consider sugars.Flatus, bloating, cramps, diarrhea; may impair absorption when GI transit accelerated, separate ~2 h per lecture.BM response days 2–3; bloating/electrolytes if chronic diarrhea.
Glycerin suppository [OTC] | adult 2.6 gInsert 1 suppository PR once daily to BID or PRN; moisten, retain ~15 min. Onset 15–60 min. Use for short rescue.Rectal fissure, fistula, severe hemorrhoids/proctitis, obstruction.Rectal irritation/burning; no substantial systemic DDIs.Passage within 1 h; rectal bleeding/pain.
Magnesium hydroxide (Milk of Magnesia) [OTC] | common 400 mg/5 mL2.4–4.8 g PO at bedtime or divided (e.g. 30–60 mL using 400 mg/5 mL); acute short-course only. Onset 0.5–6 h.CKD/renal failure, heart disease, severe dehydration, bowel obstruction; frail elders.Cramps, diarrhea, hypermagnesemia and fluid/electrolyte disorder; chelates quinolones, tetracyclines, iron, levothyroxine, digoxin.BM within hours, weakness/confusion/bradycardia in renal risk.
Sodium phosphate enema [OTC] | typical adult ~120 mLOne adult rectal enema (~120 mL; 26.4 g phosphate per lecture), 2–15 min onset. DO NOT repeat routinely or use without label check.Renal impairment, dehydration, HF, elderly frailty, obstruction; children require specific guidance.Severe phosphate/calcium and renal abnormalities, rectal burning; interacting nephrotoxins.Stool within 15 min; urgent assessment if severe pain or no response.
Bisacodyl [OTC] | 5-mg enteric tabs, 10-mg suppositoryPO 5–10 mg at bedtime PRN, onset 6–12 h; PR 10 mg once daily PRN, onset 15–60 min. Short rescue/occasional use.Bowel obstruction, acute surgical abdomen, severe dehydration; enteric coating—do not crush.Cramps, diarrhea, hypokalemia if overused. Separate ENTERIC-COATED oral form 1–2 h from milk, antacids, H2RA or PPI (early dissolution); caution diuretics/digoxin if electrolyte loss.BM next morning or in 1 h rectally; stool/abdominal cramps, electrolytes if repeated.
Sennosides / senna [OTC] | 8.6-mg tablet2–4 tabs PO at bedtime; lecture maximum 4 tabs BID (68.8 mg/day). Onset 6–12 h. Titrate to minimum.Obstruction, severe dehydration, acute unexplained abdominal pain.Cramps, diarrhea, urinary/stool discoloration; hypokalemia with prolonged excessive use → digoxin/diuretic concern.Next-day BM, cramping; avoid chronic uncontrolled use.
Docusate sodium [OTC] | 100-mg capsule100 mg PO BID; onset 12–72 h. Evidence weak; not preferred to treat established chronic constipation.Obstruction, nausea/vomiting with acute abdominal pain; concomitant mineral oil.Mild nausea/cramps; facilitates absorption of mineral oil, increasing toxicity.Stool softening/straining at 2–3 d; switch if ineffective.
Mineral oil [OTC] | PO solution / rectal enemaRectal 60–150 mL PR as occasional rescue (~2–15 min); oral 15–45 mL at bedtime sitting upright (~6–8 h); only short term <1 week if alternatives unsuitable.Avoid PO with dysphagia, frailty, children, bedridden or aspiration risk; obstruction.Lipoid pneumonia if aspirated, seepage; malabsorption fat-soluble vitamins and oral contraception; avoid with docusate.Respiratory symptoms after aspiration, leakage; avoid long-term use.
Linaclotide [Rx; NOT MACS] | 145-microgram capsule145 micrograms PO once daily ≥30 min before first meal; assess response ~1–4 weeks, trial ~8 weeks if prescribed.Known/suspected bowel obstruction; avoid children, particularly <6 y; indication-specific adult dose.Diarrhea, abdominal pain, headache; low systemic DDIs.BM frequency, severe diarrhea/dehydration after start.
Plecanatide [Rx; NOT MACS] | 3-mg tablet3 mg PO daily with/without food, adult; onset ~1 day to 1 week; evaluate after several weeks.GI obstruction; avoid young children; adult indication.Diarrhea/dehydration; minimal systemic interactions.Diarrhea and spontaneous BMs first week.
Prucalopride [Rx; NOT MACS] | 1/2-mg tablet2 mg PO daily (often 1 mg in older/frail or severe renal impairment; lecture 1–2 mg >65); discontinue if ineffective by 4 weeks.GI perforation/obstruction, dialysis/severe renal impairment depending product, IBD severe active disease.Headache, nausea, diarrhea; possible interactions noted with ketoconazole, erythromycin, digoxin; renal dosing.BM within days–4 weeks, headache/GI tolerance; refer for serious mood change.
Naloxegol / methylnaltrexone [Rx; NOT MACS] | product-specificPAMORAs for refractory OIC after appropriate laxative regimen, not routine OTC; exact product doses/strengths not supplied in lecture—verify monographs.Known/suspected GI obstruction, risk of perforation; opioid antagonist combinations.Abdominal pain, diarrhea, rare withdrawal; naloxegol strong CYP3A4 interacting drugs.BM response in days; withdrawal symptoms and abdominal pain.
FOLLOW-UP TIMELINE: Acute: BM within 1–3 d. Bulk onset 12–72 h; PEG 48–96 h; stimulant 6–12 h; glycerin/enema within 15–60 min. Check acute cases within days and chronic pattern after 2–4 weeks; titrate then consider taper after a month of stable habit. Avoid salt-based agents in CKD/cardiac disease; repeat electrolytes/renal tests if high risk.
High-yield counselling / differential: OIC: start stimulant when initiating opioids (unless contraindicated), add PEG/osmotic, use rectal rescue if needed, rule out impaction; AVOID bulk-forming and docusate alone as primary OIC treatment. Pregnancy: lifestyle → bulk → osmotic → short-term stimulant; children require age/weight-specific, clinician-guided regimens and red-flag exclusion.

08 | Acute diarrhea and travellers’ diarrhea

OTC self-care only; antibiotic treatment requires appropriate prescriber (not a diarrhea MACS indication)Lecture basis: GI 04 slides 3–27

Risk factors / causes

Infectious fecal-oral exposure (food/water, daycare, travel, contacts); medications: antibiotics, metformin, Mg, colchicine, PPIs, SSRIs, thyroid hormone, caffeine, laxatives; lactose/other intolerance. Travel risk: contaminated food/water, ETEC/EAEC, Campylobacter, Shigella, Salmonella, Giardia, norovirus.

Clinical presentation

≥3 loose stools/24 h, fluidity/frequency increase. Acute <14 d, persistent 14–30 d, chronic >30 d. Mild TD: tolerable; moderate: interrupts activity; severe: incapacitating or ANY dysentery. Assess stool blood/mucus, fever, abdominal pain, recent antibiotics and dehydration.

When to REFER / exclude self-care

Same-day evaluation: blood/melena/mucus, fever >38.5 °C (or >38 °C in infant <3 mo), marked pain/cramps, severe dehydration, ongoing vomiting >4 h, weight loss, recent antibiotic use/C. difficile concern, toxic appearance, prolonged course or failure to improve after 48 h; urgency increased in infants/frail/immunocompromised.

Complications + goals

Complications: Hypovolemia, AKI, electrolyte imbalance, hypoglycemia in infants, malnutrition; invasive bacterial disease/hemolytic uremic syndrome depending pathogen.

Goals: Replace fluid/electrolytes and maintain intake; reduce troublesome stools while not masking invasive infection; prevent transmission.

First-line counselling / non-drug treatment: ORS is FIRST LINE (glucose–sodium cotransport; not a pathogen cure). Continue age-appropriate usual food, small frequent sips, avoid high-sugar drinks, alcohol and excessive caffeine. Handwash with soap and water (especially after diaper changes), food/water precautions for travel.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Oral rehydration solution (Pedialyte/Hydralyte) [OTC] | prepared productUse correctly mixed commercial ORS; adults sip often and replace ongoing stool losses; children use weight/age-appropriate dosing per clinical guidance. No one universal volume provided by slide.Unable to tolerate fluids, shock/ileus, severe dehydration → emergency IV fluid assessment.Usually safe; inappropriate mixing may disturb sodium.Urine output, dizziness, thirst, weight, tears/wet diapers; assess after each illness day.
Psyllium [OTC] | typical 3.4-g doseFor nonspecific mild diarrhea, may use soluble fibre with sufficient water per product; no self-treatment >48 h. Pregnancy-preferred symptomatic option per lecture.Dysphagia, obstructive disease, inadequate hydration; not a substitute for ORS.Bloating, impaired oral-med absorption; separate ~2 h.Stool form at 24–48 h and hydration.
Bismuth subsalicylate (Pepto-Bismol) [OTC] | 262-mg chewableFor acute diarrhea or TD: 524 mg PO q30–60 min PRN, max 8 doses/24 h (16 ×262-mg tablets); generally ≤2 d for illness. TD prevention in adults: 524 mg BID (low), QID (standard), or 1,048 mg QID (high) for no more than 3 weeks—NOT routine recommendation.Salicylate allergy, active bleeding/ulcer, anticoagulant use, pregnancy, <12 y and avoid in <18 with viral illness; renal disease.Black stool/tongue, tinnitus with high use, nausea/bleeding; ASA/NSAIDs, warfarin/DOACs and tetracycline interaction.Reduced stools in 24–48 h, hydration, salicylate toxicity.
Loperamide (Imodium) [OTC] | 2-mg capsule/tablet4 mg PO initially then 2 mg after each loose stool, max 16 mg/day per lecture; check the exact Canadian OTC package maximum. ONLY short-term ≤48 h.Bloody diarrhea/dysentery, high fever, C. difficile, suspected invasive infection, ileus, severe colitis; <2 years contraindicated.Constipation, cramps, ileus; serious arrhythmias at overdose or with interacting P-gp/CYP3A4/2C8 inhibitors; avoid supra-label doses.Stool count within hours; distention, fever, dehydration, no improvement at 48 h.
Diphenoxylate 2.5 mg / atropine 0.025 mg tablet (Lomotil) [Rx; NOT MACS]Lecture: 2 tabs PO QID, OR 2 tabs once then 1 tab after each loose BM; max diphenoxylate 20 mg/day. Brief ≤48-h relief if appropriately prescribed.Invasive infection, bloody diarrhea, severe hepatic disease, children (lecture avoid <6 and generally all pediatrics), pregnancy/breastfeeding.Sedation, dry mouth, urinary retention, constipation, ileus; opioids/alcohol/sedatives additive CNS depression.Bowel frequency, sedation and anticholinergic toxicity; refer worsening.
Azithromycin [clinician-directed Rx, NOT MACS] | 250/500-mg tabsTD: 1,000 mg PO once OR 500 mg PO daily x 3 d; single dose may be split for tolerability. Preferred for febrile diarrhea/dysentery and some fluoroquinolone-resistant regions; individualized by prescriber.Macrolide allergy; QT prolongation/arrhythmia risk, liver disease.Nausea/diarrhea, QT; QT-prolonging drugs (e.g. some antipsychotics/antiarrhythmics), warfarin may need INR monitoring.Clinical improvement in 24–48 h, fever/blood, GI tolerance.
Ciprofloxacin [clinician Rx] | 500-mg tabTD: 500–1,000 mg once OR 500 mg BID x 3 d; resistance and safety concerns may make it unsuitable.Pregnancy/pediatric restrictions, tendon disorder, myasthenia gravis, QT risk, aortic aneurysm risk, serious prior fluoroquinolone reaction.Tendon rupture, neuropathy, CNS effects, dysglycemia, C. difficile; chelation with antacids/iron; tizanidine CONTRAINDICATED, warfarin interaction.Symptom improvement ≤48 h; emergent tendon/neurologic effects.
Levofloxacin / norfloxacin [clinician Rx] | 500 mg / 400 mgTD lecture: levo 500 mg once or daily x 3 d; norfloxacin 800 mg once or 400 mg BID x 3 d. Availability/resistance must be checked; avoid routine prophylaxis.Similar fluoroquinolone major cautions; renal dose adjustments.Tendinopathy, neuropathy, QT, C. difficile; chelation with minerals.Symptoms after 24–48 h, antibiotic AEs.
Rifaximin [clinician Rx] | 550 mg marketed in CanadaLecture treatment: 200 mg PO TID x 3 d, BUT 200-mg tablets unavailable in Canada per slide; this regimen cannot simply be dispensed using 550-mg tablets. Only for NONINVASIVE diarrhea; obtain prescriber advice.Fever, blood/dysentery, suspected invasive Campylobacter/Salmonella/Shigella; rifamycin hypersensitivity.Nausea/headache; possible interaction with cyclosporine; route/strength mismatch.Need for reassessment and appropriate available strength.
Cefixime [clinician Rx] | 400-mg tabletTD lecture: 400 mg PO once OR daily x 3 d as last-line when macrolides/FQs contraindicated. Lecture cautions no TD clinical outcome data; NOT routine choice.Serious beta-lactam allergy, severe renal dysfunction dose adjustment.Diarrhea, rash, C. difficile; warfarin may increase INR.Clinical response 24–48 h.
Dukoral oral cholera vaccine [travel clinic]Not recommended routinely to prevent TD. Lecture schedule if otherwise indicated for cholera: 2 doses, ≥1 week apart, complete ≥1 week before travel; >6-week interval restart; verify destination/age requirements.<2 y, pregnancy not routinely recommended in lecture; vaccine-specific allergies; risk-benefit individualization.GI discomfort; no treatment role in ongoing diarrhea.Do not interpret as reliable TD protection; food/water precautions still essential.
FOLLOW-UP TIMELINE: Check within 24–48 h: urine output, thirst, heart rate, stool frequency, blood/fever and ability to drink. Lack of improvement or deterioration → refer. Antibiotic use reserved for appropriately assessed moderate/severe TD or high-risk case; antimicrobial choice depends on location and resistance.
High-yield counselling / differential: For TD, loperamide ALONE must not be used for fever or dysentery. Antibiotics are not routinely prophylactic; bismuth prophylaxis is rarely worthwhile given QID burden and salicylate safety issues. ORS—not antimotility therapy—is the cornerstone.

09 | Nausea/vomiting: cause-first triage, motion sickness, PONV

OTC symptomatic care; most antiemetic Rx indications listed here are NOT BC MACSLecture basis: GI 07 slides 5–61

Risk factors / causes

Motion: age 3–12, female sex, migraine, anxiety, hormonal shifts, poor ventilation. General: gastroenteritis, pregnancy, opioids, metformin, antibiotics, digoxin, chemotherapy, surgery, CNS disease, DKA/uremia, obstruction or pancreatitis. PONV: female, nonsmoker, age <50, past PONV/motion sickness, volatile general anesthesia, postoperative opioids.

Clinical presentation

Nausea, retching, emesis +/- pallor, sweating, salivation, dizziness. Motion = travel/visual–vestibular mismatch. Opioid onset often soon after start/escalation. PONV generally first 24 h after surgery. GI infection may coexist with diarrhea/fever; check vomitus for blood/bile and volume.

When to REFER / exclude self-care

Immediate evaluation for blood/coffee-ground or bilious emesis, severe abdominal pain/fever, confusion, head injury, dehydration, major weight loss, persistent >3 d unexplained, child vomiting >6 h per slide, no urine/significant lethargy, pregnancy with poor intake, suspected DKA/obstruction/cardiac event; infants require lower threshold.

Complications + goals

Complications: Dehydration/hypovolemia, hypo-/hypernatremia or hypokalemia, AKI, aspiration, tears (Mallory–Weiss), undernutrition, poor adherence; PONV may disrupt wound closure.

Goals: Stop or reduce emesis, maintain oral hydration/med absorption, identify underlying cause, avoid treatment AEs, prevent recurrence.

First-line counselling / non-drug treatment: Small frequent sips commercial ORS; bland small meals, avoid odours/fatty/spicy foods, no lying flat after meals. For motion: sit front or centre boat, look at horizon, ventilate, minimize head motion, avoid reading; P6 acupressure can help some. For opioids: evaluate analgesia, lower/rotate opioid only with prescriber. For PONV: prevention chosen by anesthesia team.
Drug / strength / statusDose · frequency · durationContraindications / precautionsAdverse effects / interactionsWhat to monitor
Dimenhydrinate (Gravol) [OTC] | 50-mg tabs, liquid/suppsADULT oral: 50–100 mg q4 h PRN (max 400 mg/24 h per Health Canada standard); dose ≥30 min, ideally 1–2 h, before travel. 2–6 y: 12.5–25 mg q6–8h, max 75 mg/d; 6–12 y: 25–50 mg q6–8h, max 150 mg/d; under 2 clinician. Short period only.Narrow-angle glaucoma, urinary retention/BPH, frailty/delirium, severe respiratory disease, hypersensitivity.Drowsiness, dry mouth, blurred vision, constipation; paradoxical agitation in children; additive alcohol, opioids, benzodiazepines, other antihistamines/anticholinergics.Sedation/driving and relief within first few hours; adequate intake. Pediatric trial at home before travel per lecture.
Diphenhydramine [OTC] | 25/50 mg tabletsADULT common anti-motion dose 25–50 mg PO 30–60 min before travel and q4–6 h PRN; maximum per product label; not preferred to dimenhydrinate.Same anticholinergic cautions; children may have paradoxical excitement.Greater sedation/dry mouth, drug interactions with CNS depressants/anticholinergics.Response and sedation at travel start.
Promethazine [Rx depending formulation] | 25-mg tabletAdult motion sickness 25 mg PO 1–2 h before travel; repeat per prescriber if needed. Lecture does not give exact repeat schedule.Children under 2 (respiratory depression), sedatives, respiratory disease, narrow-angle glaucoma, elderly frailty.Marked sedation, anticholinergic effects, hypotension; opioids/benzodiazepines/alcohol additive; QT risk.Sedation/respirations and travel response.
Meclizine [not commercially available in Canada per lecture] | 25/50 mg historicalNot a readily marketed Canadian OTC option. Motion sickness adult 25–50 mg once before travel in other jurisdictions; Canadian compounding only if appropriately prescribed.As antihistamine; availability limits.Sedation/dry mouth; additive CNS depression.Do not counsel as freely available BC retail stock.
Scopolamine transdermal (Transderm-V) [discontinued in Canada] | historical 1.5-mg patchHistorical slide: apply behind ear 4–12 h before travel; remove after 72 h, wash hands. NOT a currently marketed Canadian patch.Avoid in children and pregnancy per lecture; narrow-angle glaucoma, urinary retention, elders/cognitive impairment.Dry mouth, blurred vision, confusion; additive anticholinergic effects.Not a standard retail recommendation; check alternatives.
Ginger / P6 acupressure [non-drug / NHP]P6 massage ≥5 min q4 h per lecture. Ginger for PONV study 1 g PO 1 h before induction under anesthesia oversight; motion sickness dose evidence variable.Ginger supplements caution when taking anticoagulants or before surgery; allergy.Heartburn/GI upset possible; potential bleeding interactions at high supplemental doses.Patient-reported nausea relief; not alternative to hydration.
Ondansetron [Rx; NOT nausea MACS] | 4/8-mg oral forms; IVPONV prophylaxis 4–8 mg IV near end of surgery per lecture. Outpatient oral regimens indication-specific and NOT supplied by lecture—verify prescribing protocol.Congenital long-QT, other QT drugs, severe hepatic impairment (dose cap); apomorphine combination contraindicated.Constipation/headache, QT prolongation; serotonergic drugs may rarely cause serotonin syndrome.ECG/electrolytes if QT risks, nausea and bowel function.
Palonosetron [hospital Rx] | IV 0.075 mgPONV prevention 0.075 mg IV at anesthesia induction per lecture.Known allergy, caution QT predisposition.Headache, constipation; serotonergic co-medication caution.Hospital PONV response in first 24 h.
Droperidol [hospital Rx] | IV 0.625–1.25 mgPONV prophylaxis 0.625–1.25 mg IV near end of surgery per lecture.QT prolongation, electrolyte abnormalities, Parkinson disease, CNS depression.QT/TdP, hypotension, EPS; additive QT agents and sedatives.ECG/electrolytes per local anesthesia protocol; EPS.
Haloperidol [hospital Rx] | 0.5–2 mg IM/IVPONV prophylaxis 0.5–2 mg IM/IV per lecture, specialist-administered.Parkinson disease/Lewy-body dementia, prolonged QT, severe CNS depression.EPS/akathisia, QT, sedation; antipsychotics/QT and CYP-interacting agents.QT and movement disorder observations perioperatively.
Aprepitant [hospital Rx] | 40/80-mg capsulePONV prevention 40–80 mg PO near induction per slide; clinical regimen protocol-specific.CYP3A4 interacting drugs; assess contraception interaction.Fatigue, headache, hiccups; reduces hormonal contraceptive effectiveness, increases exposure to some CYP3A4 substrates (e.g., dexamethasone).Vomiting first 24 h, interaction reconciliation.
Dexamethasone / methylprednisolone [hospital Rx]PONV prevention: dexamethasone 4–8 mg IV at induction; methylprednisolone 40 mg IV at induction per lecture.Infection concerns, hypersensitivity; caution diabetes/hyperglycemia, active ulcer.Transient hyperglycemia, insomnia, GI upset; NSAIDs may increase GI ulcer risk.Perioperative glucose (diabetes), infection risk.
Perphenazine / metoclopramide [hospital or clinician Rx]PONV slide: perphenazine 5 mg IM/IV; metoclopramide 25–50 mg IV perioperatively; these are HIGH/specialist protocols, NOT retail dosing. Other nausea regimens require monograph check.Metoclopramide: obstruction/perforation/bleeding, epilepsy, Parkinson, tardive dyskinesia history. Perphenazine: QT/EPS risks.Akathisia, dystonia, tardive dyskinesia, sedation; antipsychotics/other EPS agents and QT drugs add risk.Neurological effects, agitation, QT when indicated. Do not extrapolate these doses to outpatient patients.
Domperidone [Rx; NOT MACS] | 10-mg tabsNo N/V dose specified in lecture; use only per authorized prescriber/monograph, not for generic OTC nausea.Known prolonged QT, heart disease, electrolyte disturbance, strong CYP3A4 inhibitors and QT drugs.QT/arrhythmia, prolactin effects; macrolides/azole antifungals high-risk co-prescription.ECG/electrolytes if appropriate, symptom response and shortest use.
FOLLOW-UP TIMELINE: Mild motion nausea: assess after first trip/dose; limit use to travel only. Gastroenteritis: every few hours verify ORS tolerated and urine output. If opioid nausea persists, reassess opioid and antiemetic within 24–48 h. PONV: hospital team monitors first 24 h and selects rescue from DIFFERENT drug class; >6 h since last short-acting dose if considering same class. Escalate promptly for listed red flags.
High-yield counselling / differential: Antiemetic selection by mechanism: vestibular H1/M1 → dimenhydrinate or other sedating antihistamine; CTZ dopamine → dopamine antagonists; peripheral/vagal serotonin → 5-HT3 antagonists. Anti-nausea does not cure bowel obstruction, DKA or dehydration. PONV slides cover hospital practice rather than BC pharmacist independent minor-ailment prescribing.

10 | Topical OTC analgesics and localized MSK pain

BC MACS: musculoskeletal pain — Schedule I NSAIDs only; topical OTC options are recommended (not prescribed)Lecture basis: MSK 07 slides 8–45

Risk factors / causes

Overuse, strain/sprain, osteoarthritis (superficial joints), repetitive work/sport, trauma. Check age; pregnancy, CKD, CVD, peptic ulcer/bleeding, anticoagulants, aspirin-sensitive asthma; exposure to other oral or topical NSAIDs; skin condition and location.

Clinical presentation / complications

Localized movement-related pain/tenderness; acute sprain may have swelling/bruising and limited ROM; OA mechanical pain/stiffness. Consider neuropathic pain, radiculopathy and inflammatory or infectious disease. Complications: impaired mobility, chronic pain; burns or salicylate toxicity from misuse.

Refer / do not self-treat

Immediate: deformity, neurovascular loss, severe trauma, inability to bear weight (Ottawa ankle/foot rules when applicable), hot swollen joint with fever, chest/back vascular red flags. Urgent/routine: persistent >7–14 d, enlarging swelling, neurological weakness, unexplained weight loss, nocturnal unrelenting pain, large-area application requested.

Goals / treatment selection

Reduce pain, improve movement/function, reduce use of systemic medications and avoid adverse reactions. For acute peripheral MSK pain a topical NSAID has stronger evidence than counterirritants; deeper hip/back lesions respond less reliably.

Non-drug / prevention: Relative rest first 24–48h, protect/compress/elevate injured limb, gentle progressive mobilization, tailored exercise/physiotherapy; avoid prolonged immobilization. Do not place heating pads or occlusive wraps over medicated creams; wash hands after application; avoid broken skin.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Diclofenac diethylamine 1.16% gel (OTC; topical NSAID)Thin layer over affected joint/soft tissue three to four times daily; 2 cm strip ≈1 g covers ~200 cm² in lecture example. Typical acute sprain trial up to 7 days; label may permit 7–14 days depending on indication.NSAID hypersensitivity/aspirin-exacerbated respiratory disease; avoid in third trimester, on wounds, with severe renal/GI/CV risk or large-area prolonged use. Confirm age and product label.Irritant dermatitis, dryness; systemic GI/renal/CV effects possible with high-dose/area; avoid combining with oral NSAIDs if possible, watch ACEi/ARB + diuretic + NSAID and anticoagulants.Pain/function after 3–7 days; rash or wheeze immediately; review if ineffective after 7 days.
Diclofenac diethylamine 2.32% gel (OTC; extra strength)Apply ~2 g (4 cm strip) twice daily to affected area; lecture example max 4 g/day for product. Confirm actual pack insert/site and age.Same NSAID contraindications as 1.16%; not for mucosa/eyes; avoid occlusion and external heat.Skin irritation; low but not absent systemic exposure; higher risk with concomitant oral NSAIDs, warfarin, nephrotoxic drugs.Pain and mobility at days 3–7; safety review with persistent application beyond label period.
Capsaicin 0.025% / 0.075% cream (OTC; capsaicinoid)Small amount to intact skin 3–4 times daily; effect requires consistent use for ~2–4 weeks (more established for some neuropathic/OA pain than acute sprain). Wash hands after.Avoid broken skin, eyes, mucous membranes, heat/bandaging, acute highly inflamed injury; check product/age.Initial burning, erythema, coughing from aerosolization; avoid additional irritant creams or heat (burn risk).Tolerance of burning first days; reassess analgesia 2–4 weeks; stop for blistering.
Methyl salicylate (≈10–30%) ± menthol/camphor (OTC; counterirritant)Apply thin film according to label, often up to 3–4 times/day; rub gently. Formulations variable (e.g., Rub A535 methyl salicylate 18% + camphor 1% + menthol 0.75%).Avoid ASA allergy, bleeding disorders, children with salicylate risk, pregnancy unless cleared, large areas, heat, occlusion or broken skin.Warfarin: salicylate absorption may increase INR/bleeding; skin burns, irritant/allergic dermatitis, rare systemic salicylate toxicity.Assess symptom relief after several days; review skin, bruising, tinnitus/nausea/salicylate symptoms if overused.
Menthol 2–5% / camphor / eucalyptus oil (OTC; counterirritants)Use label-specific thin application, usually ≤3–4 times/day; concentrations differ widely by product. No standardized course.Avoid babies/young children depending on ingredient, sensitive skin, damaged skin, mucosa, occlusive dressings or external heat.Cooling/burning/irritation; camphor ingestion is toxic, including seizures; keep away from children. Evidence of benefit limited.Pain/skin tolerance within 3–7 days; stop irritation.
Arnica topical preparations (OTC natural product)Use exact labelled frequency and formulation only; no established evidence-based dosing for sprain benefit.Plant-family allergy; do not apply on open wounds; avoid oral non-standard arnica toxicity.Contact dermatitis; limited efficacy and variable natural health product quality.Trial within a few days, discontinue if ineffective; avoid replacing more effective care.
Follow-up / monitoring: Assess pain intensity, ROM, function and ability to bear weight at 3–7 days; examine skin with every refill/use and ask about oral NSAIDs, renal/GI/CV symptoms, warfarin. Persistent pain or deterioration requires reassessment.
Counselling pearl / evidence: MACS "musculoskeletal pain" permits prescription NSAIDs within the listed category, not every topical analgesic merely because it is sold OTC. Topical diclofenac has better evidence than warming counterirritant rubs.

11 | Uncomplicated lower urinary tract infection (acute cystitis)

BC MACS: uncomplicated UTI — antibiotic Schedule I drugs; complicated UTI/pyelonephritis excludedLecture basis: IID 16 pp. 2–13 (especially pp. 6–10)

Risk factors / causes

Urinary anatomy, sexual activity/new partner, spermicide, previous UTI, menopause/vaginal atrophy, incomplete voiding; recent antibiotic exposure/resistant isolate, diabetes with poor control, immunosuppression, urinary tract abnormalities/catheter and stones increase complicated infection risk. E. coli predominant.

Clinical presentation / complications

Acute dysuria + frequency/urgency ± suprapubic discomfort and cloudy urine, WITHOUT fever, flank pain, vomiting or systemic illness. Distinguish vaginitis/STI (discharge, itch, pelvic pain). Pyelonephritis: fever, chills, flank/CVA pain, nausea/vomiting. Complications: ascending infection, renal scarring rarely, bacteremia/urosepsis.

Refer / do not self-treat

Immediate/urgent: fever/chills, flank pain, sepsis, inability to tolerate fluids, pregnancy, suspected obstruction. Refer for male/prostate symptoms, catheter, urinary anomaly, immunosuppression/poorly controlled diabetes, significant renal impairment, first unclear diagnosis, recurrent/relapsing within 1 month, persistent >2 weeks, suspected STI/vaginitis, age <16, LTC residence, no improvement by 48h. The 2025 lecture flags CrCl <60 mL/min for referral; nitrofurantoin-specific avoidance threshold is <30 mL/min.

Goals / treatment selection

Eradicate infection, resolve pain/frequency promptly, avoid pyelonephritis/sepsis and antimicrobial resistance. For low-risk typical cystitis, choose a short narrow regimen; compare prior cultures and local resistance, recent antibiotics, pregnancy and renal function.

Non-drug / prevention: Hydration to thirst (avoid excessive forced water), do not delay voiding; analgesic acetaminophen if suitable. Cranberry/D-mannose may be discussed for prevention with uncertain or variable evidence, not treatment. Do not treat asymptomatic bacteriuria routinely: important exceptions include pregnancy and selected urologic procedures.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Nitrofurantoin monohydrate/macrocrystals 100 mg (Macrobid; BC MACS)100 mg orally twice daily WITH FOOD for 5 days. Must not use for pyelonephritis; confirm product as BID versus QID form.Avoid if eGFR/CrCl <30 mL/min (local guidance may be more conservative), history of nitrofurantoin-related liver/lung toxicity; G6PD deficiency, near term pregnancy/neonates: specialist check.Nausea, headache, brown urine; rare pulmonary/hepatic injury and neuropathy. Antacids with magnesium trisilicate reduce absorption; probenecid reduces renal excretion.Dysuria/urgency begin improving within 24–48 h; review if persistent at 48 h. Immediate stop/refer for dyspnea, cough, jaundice or neuropathy.
Nitrofurantoin macrocrystals 50–100 mg (alternative formulation)50–100 mg PO four times daily for 5 days when appropriate and available; differs from modified-release BID product.Same safety as above; swallowing, dosing burden and adherence must be considered.More frequent GI complaints; same rare serious toxicities.Check correct formulation and adherence at 48 h.
Fosfomycin tromethamine 3 g granules/sachet (Monurol; BC MACS)Dissolve 3 g sachet in ~½ cup cold water; take immediately ONCE (single dose), ideally 2–3 h after meal, often at bedtime after voiding.Avoid for pyelonephritis or invasive infection; consider resistance and prior isolate. Limited data for severe renal impairment.Diarrhea, headache, nausea; metoclopramide lowers fosfomycin serum/urinary concentrations (avoid combination).At 48–72 h assess clinical improvement; if persistent, culture/medical review.
TMP/SMX DS 160/800 mg (BC MACS when suitable)One DS tablet PO twice daily x 3 days; only if local E. coli resistance <20% and no resistant history/recent use; tailor to C&S.Sulfonamide allergy, severe renal/hepatic impairment, pregnancy caution, G6PD deficiency, severe cytopenias. Dose adjust for renal function.Rash/SJS, nausea, hyperkalemia, creatinine increase; major interactions: warfarin (↑INR), ACEi/ARB/spironolactone (↑K), methotrexate (marrow toxicity), phenytoin.Symptoms at 48 h; monitor potassium/creatinine in risk patients, INR closely with warfarin; counsel urgent rash or mucosal lesions.
Trimethoprim 100 mg (alternative Rx within category)100 mg orally twice daily OR 200 mg once daily for 3 days where formulation/availability permits.Pregnancy/folate deficiency, significant renal impairment, prior resistance; patient-specific check.Hyperkalemia with RAAS blockers, methotrexate interaction, rash, GI upset.Symptoms 48 h; potassium/renal function if high risk.
Amoxicillin/clavulanate 875/125 mg (alternative Rx)875/125 mg PO twice daily for 5–7 days as guided by local resistance, allergy and susceptibility. Not routine first-line.Immediate penicillin allergy, prior amox-clav cholestatic liver injury, dose considerations for CKD.Diarrhea, candidiasis, cholestatic hepatitis, C. difficile risk; warfarin may elevate INR.Symptoms 48 h; diarrheal adverse effects and rash during course.
Cephalexin 250–500 mg / cefixime 400 mg (alternative Rx)Cephalexin 250–500 mg orally four times daily x 5–7 d; OR cefixime 400 mg daily x 5–7 d, if indicated by local guidance and susceptibility.Severe beta-lactam allergy and renal dose adjustment; avoid indiscriminate broad-spectrum choices.Diarrhea/rash, candidiasis, C. difficile, possible warfarin-INR alteration.Symptom improvement by 48 h; adverse effects through treatment.
Ciprofloxacin 250 mg (reserved Rx—not routine MACS first choice)250 mg PO twice daily x 3 days for uncomplicated cystitis only if safer options inappropriate and justified by susceptibility. Avoid indiscriminate use.Pregnancy, serious FQ reactions history, QT risk, myasthenia gravis, aortic aneurysm risk; not preferred due to serious harms/resistance.Tendinopathy/rupture, neuropathy, CNS effects, dysglycemia, QT; chelation by Ca/Fe/Mg/Zn; ↑warfarin INR, tizanidine contraindicated.Review promptly for tendon, neuropathy, palpitations, CNS symptoms; clinical response 48 h.
Follow-up / monitoring: Reassess at 48 hours: improving dysuria/frequency, afebrile, hydration, drug tolerance. Failure/worsening at 48 h requires medical review and culture; no routine test-of-cure for resolved uncomplicated nonpregnant cystitis. Escalate urgently for fever/flank pain.
Counselling pearl / evidence: An older lecture may call all patients >65 or all diabetes "complicated"; use individual risk factors and current MACS eligibility. The lecture includes pyelonephritis/prostatitis regimens for contextual study, NOT independently prescribable MACS indications.

12 | Head lice (pediculosis capitis)

OTC treatment / counselling; not a BC MACS prescribing conditionLecture basis: DERM 04/05 slides 4–33

Risk factors / causes

Head-to-head contact, school/daycare household exposure, age 3–12, shared sleeping; lice do not fly/jump, do not imply poor hygiene, and pets do not transmit human head lice.

Clinical presentation / complications

Live mobile 2–4 mm insects near scalp; eggs/nits attached to shafts especially behind ears/nape; scalp itch appears weeks after first infestation; excoriations, cervical adenopathy, impetigo from scratching. A nit alone is NOT diagnostic of active infestation.

Refer / do not self-treat

Extensive scalp infection, fever, lymphadenopathy with pus, eyebrow/lash involvement, child younger than labelled age, pregnancy with uncertain product, treatment failure after two properly used courses, persistent live lice despite adherence, differential eczema/seborrhea.

Goals / treatment selection

Kill live lice, interrupt egg hatch cycle, relieve itch and prevent spread/reinfestation; use wet/dry fine-tooth comb to confirm live lice.

Non-drug / prevention: Wet comb with conditioner under good light; inspect close contacts and treat only if actively infested. Avoid shared brushes/headwear until treated; wash recent pillowcases/hats in hot wash/dryer, or bag items; do not fumigate houses, treat pets or exclude children from school solely for nits.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Permethrin 1% crème rinse (Nix, Kwellada-P; OTC)On washed, conditioner-free towel-dried hair saturate hair and scalp, leave 10 min, rinse; repeat on day 7–10 if instructed/live lice present (consider routine repeat based on regional guidance). Age ≥2 months per lecture; confirm product.Chrysanthemum/pyrethroid allergy precaution; avoid eyes; irritation not necessarily failure. Resistance is possible.Transient pruritus, burning, redness, tingling; no important systemic DDIs with correct topical use.Fine-comb for live lice after treatment and day 7–10; treatment failure means live crawling lice after correctly administered series, not just nits.
Pyrethrins 0.33% + piperonyl butoxide 3% shampoo (R&C; OTC)Saturate dry scalp/hair, leave 10 min; add water and lather then rinse; REPEAT at day 7. Verify label and age ≥2 months.Avoid chrysanthemum/ragweed/pyrethrin allergy; eye and ignition caution; resistance possible.Local pruritus, dermatitis/eye irritation; negligible routine DDIs.Check live lice after 7–10 d and following repeat treatment.
Dimethicone/dimeticone-based OTC products (concentration brand-specific)Physical suffocation/coating products; application on DRY hair and length of contact/repeat interval vary by Canadian manufacturer. Follow exact NPN/DIN label—do not transpose permethrin timing.Avoid eye contact and flammable heat exposures where formulation indicates.Temporary skin irritation; minimal systemic interaction potential.Inspect for live lice at day 7–10; retreat only per product instructions.
Mechanical wet combing alone (non-drug alternative)Work in small sections with fine-toothed comb from scalp to end; repeat every 3–4 days for at least 2 weeks until no lice found.Feasibility/adherence; can be burdensome with thick/long hair.Scalp tenderness if vigorous.Document live lice on each inspection; persistent live lice -> pharmacotherapy/reassessment.
Oral ivermectin / alternative off-label agents (prescriber only)Systemic ivermectin protocols for resistant head lice exist outside routine BC community OTC care; not standard BC head-lice MACS.Not routinely recommended for pregnancy or children <15 kg; dose based on weight and diagnosis.Potential CNS/GI adverse effects and DDIs; use prescriber assessment.After specialist-directed course; live lice, tolerability and reinfection source.
Follow-up / monitoring: Recheck 7–10 days after initial treatment and 7–10 days after scheduled repeat; persistent itch alone can continue after eradication and does not justify repeated insecticide. Refer for secondary bacterial infection.
Counselling pearl / evidence: Correct diagnosis requires one live louse; nits near scalp can persist after successful treatment. Counsel chemical versus physical mechanisms and retreatment timing.

13 | Scabies (Sarcoptes scabiei)

OTC / clinician-diagnosed; NOT one of BC MACS conditionsLecture basis: DERM 04/05 slides 38–59

Risk factors / causes

Prolonged close skin contact, institutional outbreaks, household/sexual contacts, crowded dwellings; immunosuppression and age/frailty increase crusted-scabies risk. Incubation often 2–6 weeks for first exposure, much faster upon reinfestation.

Clinical presentation / complications

Intense generalized itch WORSE AT NIGHT; itchy papules and thin burrows on finger webs, flexor wrists, axillae, beltline, buttocks, genitals; infants may have palms/soles/scalp. Complications: impetigo, post-streptococcal sequelae, crusted hyperinfestation; post-scabetic itching can last 2–4+ weeks despite cure.

Refer / do not self-treat

Confirm diagnosis or refer when atypical, newborn/infant, pregnancy uncertainty, extensive crusting or immune suppression, severe bacterial superinfection, treatment failure, large outbreaks. Urgent assessment with sepsis, rapidly worsening skin disease. Avoid treating a pruritic eruption as scabies without reasonable clinical confidence.

Goals / treatment selection

Eliminate mites and household transmission; treat ALL close/household/sexual contacts at SAME TIME even if asymptomatic; counsel expected persistent itch.

Non-drug / prevention: Use hot wash/dryer for used bed linens, clothing, towels; alternatively bag unwashables for ≥72h (more conservative longer storage in some protocols). Vacuum upholstery; no routine pesticides. Avoid close skin contact until initial treatment and appropriate timing completed.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Permethrin 5% cream (Nix Dermal Cream, Kwellada-P; Schedule II)Apply fully to clean dry skin from neck to soles including finger webs, under nails, navel and genitals; head/scalp also in infants/elderly or involved areas; leave 8–14 h then wash off. Repeat in 7 days (or 7–10 d) for typical infestation.Age <2 months requires clinician-directed choice; avoid pyrethroid allergy. Coverage failure is common. Safe choice commonly used in pregnancy and breastfeeding with individual assessment.Temporary itching, stinging, erythema or eczema; no routine systemic DDIs.Check new burrows/live mites after 1–2 weeks; do not mistake up to 4 weeks of residual itch for failure.
Crotamiton 10% cream/lotion (alternative; verify Canadian availability)Manufacturer/care protocol dependent, e.g. once daily for 2 successive days and repeat if necessary; less effective than permethrin.Not preferred in infants/pregnancy without clinician review; avoid face/mucosa.Irritation, contact dermatitis; low systemic DDI potential.Persistent new lesions after 1–2 weeks requires referral.
Precipitated sulfur 5–10% ointment (compounded; prescriber-supervised)Apply over body nightly for 3 consecutive nights (protocols vary); often considered in very young infants when needed.Messy/odorous; formulation and age-specific use require review.Irritation, dry skin; negligible DDIs.New lesions after course; refer if persistent.
Oral ivermectin (physician-directed, off-label for scabies in Canada)Typical specialist regimen 200 micrograms/kg orally, repeat after 7–14 days; in crusted scabies additional doses plus topical therapy. NOT BC MACS prescribing.Avoid routine use in pregnancy, lactation/newborn situations and children <15 kg without specialist oversight; interactions and neurologic disease require review.Dizziness, GI upset, pruritic flare; interactions with warfarin and other agents need evaluation.Specialist surveillance 1–4 weeks, confirm household/outbreak treatment and absence of new burrows.
Post-scabetic itch: moisturizers ± hydrocortisone 0.5–1% (OTC)Thin topical low-potency steroid once or twice daily for a brief course (e.g. 5–7 d) to symptomatic areas after mites treated; emollients regularly.Do not mistake untreated persistent infection or bacterial infection for post-scabetic eczema; avoid long-term steroids on face/folds.Skin atrophy with prolonged steroid use; minor local irritation.Itch can linger 2–4 weeks; assess new lesions rather than itch alone.
Follow-up / monitoring: Review treatment coverage/contact treatment at day 7 and again weeks 2–4. New burrows after correct treatment or untreated contacts -> consider failure/reinfection. Seek care for pus, fever, extensive crusting.
Counselling pearl / evidence: Difference: 1% permethrin for head lice; 5% permethrin for scabies. The entire skin surface and ALL contacts matter more than spot treatment.

14 | Rosacea — phenotype-directed treatment

Counselling / physician or NP prescription (rosacea itself is not BC MACS)Lecture basis: DERM 09 slides 5–49 (file title includes acne but contents primarily rosacea)

Risk factors / causes

Adult onset often 30–50; family tendency, fair skin (all phototypes affected), UV, heat, exercise, spicy foods, alcohol, hot beverages, stress, topical steroids, irritating scrubs/astringents, vascular reactivity; Demodex may contribute.

Clinical presentation / complications

Persistent central-face erythema/flushing ± telangiectasia, papules/pustules WITHOUT comedones; burning/stinging, sensitive dry skin; ocular gritty/red eyes; phymatous skin changes. Distinguish acne (comedones), perioral dermatitis, seborrheic dermatitis, lupus. Complications: ocular keratitis/vision risk, rhinophyma, psychological effects.

Refer / do not self-treat

Same-day for eye pain, photophobia, vision change; referral for uncertain diagnosis, severe/rapid progression, rhinophyma, steroid-induced flare, significant ocular disease or failure of 8–12 weeks of appropriate care. Rosacea is not independently prescribable as BC minor ailment.

Goals / treatment selection

Reduce inflammatory lesions and bothersome erythema, prevent triggers/ocular complications; therapy must target phenotype. Brimonidine helps erythema; anti-inflammatory creams target papules/pustules, neither fixes fixed telangiectasia.

Non-drug / prevention: Gentle fragrance-free cleanser + moisturizer, broad-spectrum SPF ≥30 each morning; identify specific individual triggers; avoid astringents/abrasive products, topical steroids on face when possible, excessive heat. Lid scrubs/warm compresses and artificial tears for mild ocular symptoms pending evaluation.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Brimonidine 0.33% gel (Onreltea; prescription outside MACS)Thin layer once daily over affected persistent erythema; onset ~30 minutes, peaks ~3 h, lasts ~10–12 h.Caution with cardiovascular/cerebrovascular disease, orthostatic hypotension, severe depression, alpha-agonist sensitivity; avoid eyes/lips.Flare/rebound erythema, flushing, pallor, irritation; caution other antihypertensives and MAO inhibitors.Assess same-day cosmetic response and rebound after use; reassess 2–4 weeks.
Metronidazole topical 0.75% gel/cream or 1% cream/gel (prescription)0.75% often apply twice daily; 1% generally once daily, depending on DIN/product. Continue 8–12 weeks then maintenance.Hypersensitivity; do not apply to eyes; safety in pregnancy assessed case-by-case.Irritation/dryness/burning; systemic DDI minimal, though monitor warfarin if very extensive application.Inflammatory lesion count and irritation at 3–6 weeks, decision at 8–12 weeks.
Azelaic acid 15% gel (Finacea; prescription)Thin layer once or twice daily per product/clinician (lecture uses once daily); titrate based on tolerability; 8–12 weeks initial.Hypersensitivity; avoid mucosal use, highly irritated skin.More burning/stinging/itching than metro; few systemic DDIs.Tolerance week 1–2, papules at weeks 3–6; reassess 8–12 weeks.
Ivermectin 1% cream (Rosiver; prescription)Thin layer to affected facial regions once daily for up to ~12–16 weeks; reassess response at 12 weeks.Hypersensitivity; pregnancy/breastfeeding require review; not lice/scabies regimen.Temporary burning/dry skin; minimal systemic DDIs.Papule/pustule reduction by weeks 4–8, reassess at 12 weeks.
Doxycycline 40 mg modified release or 100 mg (systemic prescriber)For moderate-to-severe inflammatory lesions: 40 mg modified-release daily where Canadian product available; alternatively 100 mg daily according to prescriber, often 6–12 wk, generally limit antibiotic exposure.Pregnancy, children <8 y, tetracycline allergy, photosensitivity risk, esophageal disease.Photosensitivity, esophagitis, GI upset, yeast infection; separate calcium/iron/antacids by ≥2–3 h; warfarin INR interaction.Inflammatory lesions and skin tolerance at 4–6 weeks; resistance/safety review by 8–12 weeks.
Oxymetazoline 1% facial cream (US rosacea product)US prescription option for fixed erythema; not a routine Canadian rosacea product. Do NOT substitute 0.05% nasal decongestant spray onto face.Similar vasoconstrictor cautions; Canada availability not established.Rebound erythema/irritation potential.Not a standard Canadian counselling recommendation.
Follow-up / monitoring: Follow-up 3–6 wk for lesion reduction and local tolerability; full assessment 8–12 wk, then long-term maintenance/trigger prevention. Immediately refer painful/red eyes with vision symptoms.
Counselling pearl / evidence: Acne-vs-rosacea: papulopustular rosacea does not produce comedones; irritant acne products may worsen rosacea. The uploaded "Acne Rosacea" lecture focuses on ROSACEA.

15 | Onychomycosis (fungal nail infection)

BC MACS: fungal nail infections — TOPICAL Schedule I drugs onlyLecture basis: DERM 12 slides 3–39

Risk factors / causes

Dermatophytes (Trichophyton rubrum), tinea pedis, older age, male sex, occlusive shoes, sports/pools, repetitive nail trauma, diabetes, peripheral vascular disease, immunocompromise, affected household members. Fingernails may involve yeast.

Clinical presentation / complications

Distal/lateral nail yellow-white discolouration, thickening, crumbling, onycholysis, subungual debris; superficial white patches; proximal nail involvement suggests impaired immunity. Differentials psoriasis, trauma, lichen planus, melanoma. Complications cellulitis/foot ulcer in diabetes, discomfort and recurrence.

Refer / do not self-treat

Refer if proximal disease, >50% nail, matrix/lunula involvement, multiple extensively thickened nails, significant pain, rapid pigment change/melanonychia, immunocompromised/poor circulation/diabetic foot, children, failed appropriate topical treatment or unclear diagnosis. Mycology (KOH/culture/PAS) recommended especially before systemic therapy.

Goals / treatment selection

Mycological cure plus gradual regrowth of normal nail (may take ~9–18 months toenails); prevent recurrence by treating tinea pedis and reducing moisture. Topicals suitable for limited distal disease with matrix spared; oral treatment requires another prescriber.

Non-drug / prevention: Trim nails, gentle filing/debridement, change socks daily, ventilated footwear, clean shoes, treat concomitant tinea pedis and avoid barefoot communal showers. Progress judged by CLEAR NAIL growing from base, not instantaneous disappearance.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Efinaconazole 10% solution (Jublia; TOPICAL BC MACS)Once daily to entire affected nail, folds, nail bed, undersurface and distal tip for 48 weeks; lecture ~1 drop/nail or ~2 drops great toenail, subject to applicator.Not suitable for severe matrix disease needing systemic treatment; avoid eye/mucosal exposure, assess child/age indication and pregnancy.Vesicles, dermatitis, erythema; low systemic interactions.Photo/document healthy new nail at 12, 24 and 48 weeks; mycological outcomes after full course and additional regrowth.
Ciclopirox 8% nail lacquer (Penlac; prescription, TOPICAL category)Apply nightly once daily to nail and surrounding skin for up to 48 weeks; remove built-up coats about weekly using alcohol per label; trim weekly and debride periodically.Limited efficacy for severe disease; allergy, severe barrier problems; confirm current marketed Canadian product/DIN.Local erythema, burning, nail shape changes; no substantial DDIs.Assess adherence/clear nail at 12–24 wk; consider escalation if no response.
Propylene glycol + urea + lactic acid solution (Emtrix; OTC)Apply once nightly to nail and under free nail edge for months (often 3–6 months or more). Cosmetic/keratolytic support; not equivalent to Rx antifungal cure.Limited efficacy; avoid open painful periungual tissue.Transient local stinging, irritation or nail whitening.Appearance at 12–24 weeks; refer if worsening.
Terbinafine 250 mg orally (systemic prescriber only)250 mg by mouth daily x 6 weeks fingernails or 12 weeks toenails (for dermatophyte disease after confirmation). NOT onychomycosis MACS prescribing.Active/chronic liver disease, major liver toxicity history; evaluate renal function; pregnancy and breastfeeding need specialist review.Hepatotoxicity, dysgeusia/anosmia, rash, GI upset; CYP2D6 inhibition may raise metoprolol, TCAs, certain antidepressants.Baseline hepatic status/LFTs (and repeat based on risk/symptoms), serious rash, jaundice; nail regrowth takes months.
Itraconazole 200 mg capsules (systemic prescriber only)Continuous: 200 mg/day x 6 wk fingers or 12 wk toes; pulse: 200 mg twice daily for 1 week each month (2 pulses fingers, 3–4 toes) when appropriate.Heart failure/ventricular dysfunction, hepatic disease, pregnancy, marked interacting drugs; capsules need gastric acidity for absorption.CYP3A4 strong inhibition: simvastatin/lovastatin, some benzodiazepines/QT drugs contraindicated; edema/hepatotoxicity. PPIs reduce capsule absorption.Baseline liver/drug interaction review and follow-up 4–6 weeks; monitor edema/HF symptoms and slowly advancing normal nail.
Follow-up / monitoring: Check nail proximal clear growth every 3 months, photos, redness/irritation and adherence; treatment lasts ~48 weeks, and clinical clearance may be delayed for months after end. Reassess failed topicals/systemic-risk patients.
Counselling pearl / evidence: BC pharmacists may prescribe TOPICAL drugs for onychomycosis (e.g. efinaconazole), NOT oral terbinafine or itraconazole through MACS. Old/infected nail must grow out even after microbiologic cure.

16 | Atopic dermatitis / eczema

BC MACS: dermatitis — topical Schedule I drugs for suitable mild-to-moderate casesLecture basis: DERM 13 slides 7–65

Risk factors / causes

Personal/family atopy (asthma, allergic rhinitis, eczema), filaggrin/skin-barrier dysfunction, early childhood onset, irritant soaps/wool, low humidity, sweating/heat, scratching, colonization with S. aureus.

Clinical presentation / complications

Pruritus is hallmark; xerosis, erythema, scale, excoriations, lichenification. Infant: cheeks/extensors; child: flexural surfaces; adult: hands/flexures/eyelids. On darker skin erythema may appear violaceous/hyperpigmented. Complications: impetiginization, eczema herpeticum, sleep disruption and chronic itch-scratch cycle.

Refer / do not self-treat

Urgent: painful monomorphic punched-out vesicles/fever (eczema herpeticum), widespread infected oozing skin, cellulitis, rapidly spreading rash, eye involvement. Routine: extensive or severe, refractory >1–2 wk of correct regimen, diagnostic doubt, inadequate sleep/QOL, infants or special sites needing advanced therapy.

Goals / treatment selection

Restore barrier, rapidly suppress inflammatory flare, eliminate pruritus, minimize relapse and steroid adverse events; choose steroid potency by age, SITE, severity, duration, not merely % strength.

Non-drug / prevention: Generous fragrance-free emollient 2–3+ times/day and immediately after lukewarm bath; fragrance-free wash, short nails, avoid known triggers; avoid routine antibiotics without clinical infection. Apply steroid to inflamed lesions only, with moisturizer separately (order less important than consistent use).
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Hydrocortisone 0.5–1% cream/ointment (OTC low potency)Thin layer once or twice daily for 5–7 days on face/folds/infant sites if appropriate; body flares often 7–14 days. Hydrocortisone 2% may be Rx depending on product.Avoid untreated bacterial/fungal/herpetic lesions; caution periocular eyelid use; do not use under occlusion or on large areas without review.Burning, folliculitis; prolonged use → atrophy, striae, glaucoma if near eyes, HPA suppression with extensive use; minimal DDIs.Pruritus improves 2–3 d; signs improve within 5–7 d; review nonresponse or spreading infection.
Desonide 0.05% / hydrocortisone valerate 0.2% (low–moderate Rx topical)Apply thin layer once or twice daily for usually 7–14 days, site/formulation-dependent. Desonide favored sensitive sites compared with high potency agents.Facial/fold long-term caution, untreated skin infection, pediatric BSA/age restrictions.Atrophy with overuse; local burning, telangiectasia.Flare assessment within 1 week, taper/stop on clearance.
Triamcinolone acetonide 0.1% / betamethasone valerate 0.05–0.1% (moderate Rx)Thin layer 1–2 times/day to trunk/limb patches for ~7–14 days, then stop or intermittent maintenance if prescribed. Product potency differs by ointment vs cream.Avoid face/genitals/folds unless specifically directed, age-specific restrictions, wide areas/occlusion.Atrophy, stretch marks, hypopigmentation, systemic absorption; DDIs minimal except additive corticosteroid exposure.Response 3–7 days, skin thinning with repeated use, frequency of flares.
Mometasone furoate 0.1% / clobetasol 0.05% (higher-potency Rx; selected cases only)Mometasone thin layer usually once daily limited course; clobetasol 0.05% very high potency typically once or twice daily ≤2 weeks on thick resistant adult plaques only.Not routine MACS for delicate areas, infants, or widespread disease. Avoid infection/occlusion; confirm product-specific potency.HPA-axis suppression, atrophy, folliculitis; cataract/glaucoma risk near eyes, tachyphylaxis concern.Recheck high potency within 1–2 weeks; stop/step down when controlled.
Tacrolimus ointment 0.03% / 0.1% (topical calcineurin inhibitor; Rx)0.03% for age ≥2–15 years; 0.03% or 0.1% age ≥16 years; thin layer twice daily to active lesions until control; intermittent proactive use may be prescribed.Not for <2 yr per typical Canadian label, severe immunodeficiency, active cutaneous infection; avoid excessive UV exposure.Transient burning/stinging; avoid concomitant UV phototherapy; minimal systemic DDIs.Reassess 1–2 weeks for burning and improvement, sustained control at 4–6 weeks.
Pimecrolimus 1% cream (Elidel; Rx topical)Thin layer twice daily to eczema until clear, intermittent use for recurrence; review age/label and BC prescriber scope.Do not use on infected lesions; age restrictions per Canadian monograph; avoid immunocompromised states.Stinging/warmth, transient erythema; avoid strong UV exposure; limited systemic interactions.Improvement 1–3 weeks, if no clear response by 6 weeks reevaluate.
Dupilumab / JAK inhibitors / systemic immunomodulators (specialist-only context)Moderate–severe refractory eczema requires dermatology-directed biologic/systemic regimens and pre-treatment screening; no generic short OTC/MACS regimen.Not part of topical MACS prescribing for dermatitis.Agent-dependent infection/thrombosis/lab and other risks.Specialist monitoring schedule, labs and infection/vaccine review as indicated.
Follow-up / monitoring: Within 5–7 d: itch, sleep, erythema and extent; within 2 wk: steroid area, adherence, signs of infection/atrophy; monthly if recurrent to optimize emollient and trigger strategy. Escalate if no response after appropriate site-potency course.
Counselling pearl / evidence: Steroid POTENCY, vehicle and anatomical site matter; even low-potency drugs can cause harm if used chronically on eyelids. Tacrolimus/pimecrolimus spare skin atrophy but can sting early.

17 | Allergic and irritant contact dermatitis

BC MACS: dermatitis — topical Schedule I drugs for low-risk mild casesLecture basis: DERM 13 slides 66–81

Risk factors / causes

Exposure to soaps, sanitizers, wet work, household detergents, nickel/jewellery, fragrance, preservatives, hair dye, plants, gloves/latex, topical medication. Allergic dermatitis is delayed T-cell (type IV) sensitization; irritant type is direct barrier damage and can occur on first exposure.

Clinical presentation / complications

Usually exposure-distributed, well-demarcated itchy eczematous rash; allergic reaction appears ~24–48h after reexposure with itch prominent; irritant reaction often more burning/pain, dryness, fissures. Acute vesicles/bullae or crust; chronic lichenification. Complications: infection, occupational hand dermatitis, pigment change.

Refer / do not self-treat

Refer if >20% BSA, eyelids/genitals/face severely involved, severe blistering/ulceration, fever/spreading pus, systemic allergic symptoms, uncertain culprit, occupational recurrent exposure, no improvement 1–2 weeks or severe persistent hand eczema. Emergency for breathing difficulty/angioedema.

Goals / treatment selection

Identify and STOP offending exposure, repair skin barrier, reduce inflammation/pruritus and prevent recurrence. Patch testing for recurrent/unexplained allergic cases; distinguish irritant dermatitis from urticaria and infection.

Non-drug / prevention: Wash exposure with lukewarm water, remove contaminated clothing, cool wet compresses for weeping lesions, petrolatum/emollients frequently, gentle cleansers, protective gloves + cotton liners at work; avoid topical anesthetics or antibiotics that can sensitize.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Hydrocortisone 0.5–1% OTC topical steroidThin layer 1–2 times daily for ~5–7 days on mild limited face/folds/children if appropriate; short body course up to 1–2 wk.Do not apply to open infected lesions; avoid chronic face/genital use.Local irritation, atrophy with prolonged use; little drug-drug interaction.Pruritus/rash at 3–7 d; refer if spreading or not resolving.
Triamcinolone 0.1%, betamethasone valerate 0.05–0.1% (moderate Rx)Apply thin layer 1–2 times per day for ~7–14 days to trunk/hands/extremities with careful site assessment.Not for uncontrolled infection or sensitive sites without clinician decision; steroid allergy possible.Atrophy, hypopigmentation, striae; repeated exposure large-area systemic absorption.Response at 3–7 d; discontinue/step down once cleared.
Clobetasol 0.05% (very high-potency Rx; severe thick hand/palm lesions)Small amount to limited thick adult skin 1–2 times/day for ≤2 weeks, ONLY if appropriate prescriber assessment; generally not minor routine case.Avoid face/folds, younger children, occlusion, extensive body coverage.Atrophy, HPA suppression, superinfection; systemic corticosteroid burden.Review 1–2 wk; refractory severe cases dermatology referral.
Tacrolimus 0.03–0.1% / pimecrolimus 1% (Rx, off-label some sites)Applied twice daily to selected recurrent sensitive-site eczematous lesions under an accepted clinical approach; site, age and label must be checked.Uncertain diagnosis, active infection, immunosuppression; exposure allergy must be removed first.Transient burning; ultraviolet avoidance; limited systemic DDIs.Review by 2 weeks; escalate if persistent trigger or infection.
Oral nonsedating antihistamine (OTC symptom relief only)Cetirizine 10 mg PO daily or loratadine 10 mg daily as needed for concomitant urticaria/allergic symptoms; often little effect on eczematous itch itself.Renal impairment requires cetirizine review; age/weight and pregnancy vary.Cetirizine somnolence; minimal interactions, alcohol additive sedation in some.Symptom relief in 1–3 days; discontinue if not helpful.
Prednisone / systemic corticosteroid (other prescriber, extensive allergic reactions)Physician may prescribe short taper for severe widespread allergic contact dermatitis, especially rhus dermatitis; not a dermatitis TOPICAL-MACS drug.Infection, diabetes, GI/psychiatric complications, rebound with too-short courses.Hyperglycemia, insomnia, fluid retention, drug interactions.Physician-directed monitoring and taper according to severity.
Follow-up / monitoring: Confirm avoidance effectiveness by 48–72 h; monitor redness, itching, skin fissures/infection at 5–7 d; full healing may take 1–3 weeks depending on prior severity; refer recurrent or unclear culprit for patch testing.
Counselling pearl / evidence: When rash is sharply limited to a contact site, think contact exposure; stopping the trigger is more important than increasing steroid potency.

18 | Acne vulgaris — sourced from Acne.pdf

BC MACS: mild acne — TOPICAL Schedule I drugs only (dedicated acne lecture pending)Source: dedicated Acne.pdf (CPhA eTherapeutics print, 2022; pages 1–16)

Risk factors / causes

Pubertal androgen-driven sebum, follicular hyperkeratinization, Cutibacterium acnes and inflammation; family history, occlusive cosmetics/masks, hormonal shifts, corticosteroids, lithium, anabolic agents; may persist into adulthood.

Clinical presentation / complications

Open/closed comedones plus inflammatory papules/pustules on face/chest/back; nodules/cysts suggest severe disease. Rosacea has central redness/telangiectasia and NO comedones. Complications: permanent scarring, post-inflammatory dyschromia and psychosocial distress.

Refer / do not self-treat

Refer deep nodules/cysts, rapid severe acne, scarring, major psychological distress, suspected endocrine hyperandrogenism, pregnancy when Rx options limited, failure after 8–12 weeks of correctly used topical therapy or widespread severe disease.

Goals / treatment selection

Reduce comedones and inflammatory lesions, prevent scars and pigmentation; start with BPO or topical retinoid, and avoid antibiotic monotherapy. Visible response generally 6–8 weeks; 8–12-week assessment essential.

Non-drug / prevention: Mild gentle cleanser twice daily, noncomedogenic moisturizer and SPF ≥30, avoid picking, scrubs or harsh alcohol products. Apply retinoids to entire acne-prone area rather than only existing lesions; use pea-sized amount to dry skin. Sensitive skin: begin alternate nights.
Drug / category / scopeStrength • dose • duration / applicationContraindications / avoid / precautionsInteractions / key adverse effectsEffectiveness + safety monitoring
Benzoyl peroxide 2.5% / 5% / 10% (OTC)Thin layer once daily initially; increase to twice daily as tolerated. Lower 2.5–5% often similarly effective with less irritation; use 8–12 weeks then maintenance.Avoid allergy/severely inflamed broken skin; caution delicate areas.Dryness, bleaching clothing/hair, irritant/contact dermatitis; can oxidize tretinoin formulations—separate applications unless stabilized combination.Dryness at 1–2 weeks; lesion count at weeks 6–8; benefit at 8–12 weeks.
Adapalene 0.1% / 0.3% gel or cream (Differin; Schedule I topical MACS)Thin layer to acne-prone skin once nightly; start 2–3 nights/wk then increase as tolerated for 8–12 wk. Adapalene 0.1% + BPO 2.5% combo (TactuPump) nightly.Avoid during pregnancy/planning pregnancy; severe eczema/sunburn or skin sensitivity.Dryness, peeling, photosensitivity/irritation; avoid concurrent harsh exfoliants; BPO combo bleaches fabrics.Tolerance 2–4 weeks; comedones and inflammatory lesions by weeks 6–12.
Tretinoin 0.01%, 0.025%, 0.05%, 0.1% topical (Schedule I MACS)Pea-sized thin layer once nightly to dry acne-prone skin for ≥8–12 wk; titrate strength and frequency slowly.Pregnancy avoidance, sunburn/eczema, topical sensitization; age restrictions per formulation.Irritation, erythema, peeling, photosensitivity; separate traditional tretinoin application from BPO if formulation not compatible.Skin irritation weeks 1–4, acne at 8–12 wk.
Clindamycin 1% topical (Rx Schedule I; use WITH BPO)Thin layer once or twice daily as directed; often paired with BPO 3–5% (e.g. Clindoxyl) once daily for inflammatory acne. LIMIT antibiotic to ~8–12 weeks then nonantibiotic maintenance.Do not use as monotherapy; history of antibiotic-associated colitis/IBD and severe hypersensitivity require caution.Local dryness, rare antibiotic-associated diarrhea/colitis; combination with BPO reduces resistance.Inflammatory lesions at 6–8 weeks, diarrhea during treatment; stop if severe.
Azelaic acid 15% gel (Finacea; topical MACS)Apply thin layer once or twice daily to acne-prone skin per label and tolerance for 8–12 wk; may help post-inflammatory pigmentation.Skin sensitization; avoid eyes/mucous membranes.Stinging, burning, dryness; few systemic DDIs.Tolerance 1–2 wk; inflammatory lesion response weeks 6–12.
Dapsone 5% topical gel (Aczone; Schedule I MACS)Thin layer twice daily for inflammatory acne, if Canadian product available and suitable; verify DIN/age.G6PD deficiency/hemolysis caution; use with BPO can transiently stain skin/hair orange-brown.Dryness, local oiliness, rare hematologic effects with systemic absorption.Inflammatory lesions 8–12 weeks; hematologic symptoms in risk patients.
Oral doxycycline, isotretinoin, hormonal agents (other prescriber ONLY)Moderate/severe inflammatory or scarring acne may need systemic therapy, but not permitted under topical-only BC acne MACS.Pregnancy restrictions and agent-specific serious adverse effects.Systemic monitoring required, especially isotretinoin teratogenicity.Referral to primary care/dermatology for treatment planning.
Follow-up / monitoring: Every 2–4 weeks: tolerability, adherence and moisturization. Formal efficacy assessment at 8–12 weeks with lesion count/photos; refer if nodulocystic lesions, scarring or poor response.
Counselling pearl / source: Updated using your dedicated Acne.pdf (CPhA/eTherapeutics print, revision 2022). Treatment response frequently takes 2–3 months. Topical retinoids are comedolytic; pair topical antibiotics with benzoyl peroxide to reduce resistance. Oral isotretinoin, systemic antibiotics and systemic hormonal treatments remain outside BC MACS topical-drug scope.

19 | Acute rhinosinusitis / sinusitis

OTC management · systemic antibiotics outside BC MACSSource: HEENT 06 Sinusitis, pages 4–45

Risk factors / etiology

Recent viral URI; allergic rhinitis/asthma; smoking or second-hand smoke; nasal polyps, septal abnormalities, impaired drainage, immunosuppression; daycare/recent antibiotics may raise resistant-pathogen concerns.

Presentation / differential / complications

PODS: Pain/pressure face, Obstruction, purulent Discharge, Smell change; plus cough, dental/ear pressure, malaise. Likely viral: <10 days and improving. Suspect bacterial: ≥10 days without improvement, severe fever ≥39°C with purulent discharge/facial pain ≥3–4 days, or double worsening after initial improvement. Discharge colour alone is not diagnostic. Complications: orbital cellulitis, intracranial abscess/meningitis.

When to refer / scope limit

Emergency: orbital pain/swelling, impaired vision/diplopia, proptosis, altered mental status, severe headache with stiff neck, neurologic signs. Medical assessment: bacterial pattern, severe facial pain, prolonged fever, immunocompromise, recurrent episodes ≥4/year, chronic symptoms ≥12 weeks, significant comorbidity. BC sinusitis is not a MACS prescribing diagnosis; antibiotic selection belongs to another authorized prescriber.

Goals of therapy

Relieve facial pain/congestion, improve drainage and sleep, prevent serious complication, avoid unnecessary antibiotic exposure and resistance.

Non-drug / counselling: Encourage rest, fluids, avoidance of tobacco/irritants and correct saline rinse technique. Only sterile/distilled or previously boiled then cooled water for irrigation. Acute sinusitis is commonly viral; antibiotic benefit is limited for early/uncomplicated presentations.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Saline nasal spray / isotonic rinse (OTC)0.9% NaCl spray: 1–2 sprays/nostril PRN several times/day; high-volume saline rinse per device (often once or twice daily), as tolerated.Do not use unboiled tap water; avoid vigorous irrigation with complete blockage/ear discomfort.Transient irritation, minor burning or ear pressure; no significant systemic DDIs.Check nasal obstruction/discharge in 48–72 h; discontinue if ear pain/bleeding.
Fluticasone propionate intranasal (OTC/Rx)50 micrograms/spray: 1–2 sprays/nostril once daily (usual adult range) for 1–2 weeks if indicated; maximal effect 3–14 d.Caution recent nasal surgery/ulcers, recurrent epistaxis, untreated nasal infection; not an antibacterial drug.Epistaxis, dryness, headache; CYP3A4 inhibitors (e.g., ritonavir) may increase systemic steroid exposure.Reassess at 72 h; inspect for persistent epistaxis and pain at 1–2 weeks.
Oxymetazoline topical nasal (OTC)0.05%: commonly 1–2 sprays/nostril q12h as needed; maximum 3 days (confirm label).Uncontrolled HTN, significant CAD/arrhythmia, hyperthyroidism, glaucoma; pregnancy individualize; avoid with MAOI.Rebound congestion/rhinitis medicamentosa with prolonged use; dryness, palpitations.Stop by day 3; return if congestion rebounds.
Pseudoephedrine oral (OTC, age/product restricted)Immediate release 30–60 mg PO q4–6h as needed; max 240 mg/day adult; use only for a few days.Uncontrolled HTN, CAD, severe arrhythmia, glaucoma, urinary retention; avoid MAOI within 14 days.Insomnia, nervousness, increased BP/HR; additive stimulants and sympathomimetics.Ask about BP/palpitations/sleep within 1–2 days; stop if marked symptoms.
Acetaminophen / ibuprofen (OTC)Acetaminophen 500–1000 mg PO q6–8h PRN, conservative self-care max 3000 mg/day; ibuprofen 200–400 mg PO q4–6h PRN, max OTC 1200 mg/day. Short-term.Acetaminophen: major liver disease/heavy alcohol. Ibuprofen: ulcer/bleeding, CKD, dehydration, late pregnancy; avoid other NSAIDs.Acetaminophen: liver toxicity in overdose/combination products. NSAID: dyspepsia, AKI, GI bleed; interactions warfarin/ACEI/diuretic.Pain/fever over 48–72 h; if worsening seek assessment.
Amoxicillin (clinician-directed, NOT BC sinusitis MACS)Pediatric regimen in uploaded lecture: 40 mg/kg/day divided TID ×10 days; high dose 90 mg/kg/day divided BID–TID ×10 days for selected risk. Adult dose requires local guideline/product verification.Penicillin anaphylaxis; dose adjust for renal function; assess severity, recent antibiotics and bacterial features first.Rash, diarrhea, hypersensitivity; increased INR possible with warfarin; some severe delayed reactions.Clinician follow-up for worsening after 72 h on antibiotics or nonresponse after course.
Amoxicillin/clavulanate (clinician-directed)Lecture failure option adult 875/125 mg PO BID ×5–10 days; pediatric 7:1 formulation 45 mg/kg/day of amoxicillin component divided BID–TID ×10 days, with extra amoxicillin for selected high-dose plans.Penicillin allergy, previous amoxicillin-clavulanate cholestatic jaundice; renal/hepatic caution.Diarrhea, nausea, candidiasis, rare liver injury; interaction with warfarin (INR); C. difficile.Review treatment response by 48–72 h and adverse effects throughout; culture/referral if failure.
Levofloxacin (clinician/specialist reserve)Lecture treatment-failure option 750 mg PO daily ×5–10 days (renal adjustment); reserve when alternatives unsuitable.Myasthenia gravis, prior quinolone tendon disorder, QT risk, pregnancy/children; many serious warnings.Tendinitis/rupture, neuropathy, CNS effects, dysglycemia, QT prolongation; chelation with iron/calcium/magnesium.Close follow-up for tendon/neurologic symptoms, QT/renal concerns; not routine initial care.
Follow-up / monitoring: Self-care review at 48–72 h; most improve over 7–10 days. Refer for worsening, persistent ≥10 days without improvement or initial improvement followed by deterioration. Antibiotic patients: expect trend to improvement within 48–72 h.
Clinical pearl / evidence: Medication category ≠ authorization: BC pharmacist allergic-rhinitis intranasal prescribing does not authorize prescribing systemic antibiotics for sinusitis. Lecture antibiotic choices are included for therapeutic comparison only.

20 | Allergic rhinitis (seasonal / perennial)

BC MACS: intranasal + oral antihistamines + specified ophthalmic drugsSource: HEENT 07 Allergic Rhinitis, pages 3–34, 44

Risk factors / etiology

Genetic/atopic history, asthma, eczema; seasonal tree/grass/weed pollen and molds; perennial mites, pets and occupational allergens. Exposure intensity, indoor humidity/ventilation contribute.

Presentation / differential / complications

IgE-mediated: sneezing, nasal and eye itch, clear rhinorrhea, congestion, postnasal cough; allergic shiners, watery eyes. Early histamine phase and later congestive inflammatory phase. Intermittent vs persistent (>4 days/week AND >4 weeks); mild vs moderate/severe (sleep/activity impairment). Complications include disrupted sleep/productivity, sinus/ear symptoms and asthma destabilization.

When to refer / scope limit

Unilateral foul discharge/bleeding, high fever, facial pain, nasal polyp/obstruction, suspected foreign body, severe asthma, symptoms atypical for allergy, treatment failure after optimized 2–4 weeks; urgent swelling/breathing compromise.

Goals of therapy

Relieve itch, sneezing, rhinorrhea and obstruction; preserve sleep/function and asthma control; minimum effective continuous therapy.

Non-drug / counselling: Pollen mitigation, closed windows on high-pollen days, shower after outdoors, wash bedding, dust-mite covers if appropriate, avoid smoke. Spray technique: head neutral/slightly forward, opposite hand, aim laterally away from septum; sniff gently; do not blow nose immediately. Regular INCS gives best congestion control.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Fluticasone propionate / furoate (INCS; MACS if Schedule I)Propionate 50 mcg/spray 1–2 sprays/nostril daily; furoate 27.5 mcg/spray 2 sprays/nostril daily initially then 1 when controlled. Review individual Canadian labels.Recent nasal surgery, recurrent bleeding; review interacting strong CYP3A4 inhibitors.Epistaxis, irritation, headache; rarely perforation or thrush. Strong CYP3A4 inhibition may increase systemic exposure.Check technique/adherence at day 3–7; maximal response at day 3–14; reassess 2–4 weeks.
Mometasone / ciclesonide INCS (MACS if Schedule I)Mometasone 50 mcg/spray 1–2 sprays/nostril daily; ciclesonide 50 mcg/spray 2 sprays/nostril daily (lecture).Nasal ulceration, severe recurrent nosebleeds and untreated nasal infection; pregnancy individualized.Epistaxis, local irritation; low systemic bioavailability.Technique day 3–7 and control after 2 weeks.
Budesonide / triamcinolone / beclomethasone INCSBudesonide 1–2 sprays/nostril daily; triamcinolone 1–2 sprays/nostril daily; beclomethasone 1–2 sprays/nostril BID; strength varies by device.Local nasal infection/ulceration and recent surgery. In pregnancy, lecture recommends avoiding triamcinolone relative to others.Nosebleeds, irritation, rarely septal perforation.Monitor local tolerance first week, effect at 1–2 weeks, longer-term necessity/lowest dose.
Cetirizine (2nd-generation H1; OTC)10 mg PO daily adult; pediatric dose differs. May be used PRN for intermittent mild symptoms.Renal impairment needs dose reduction; caution driving/sedation and use with alcohol.Somnolence (relatively more than other second-gen), dry mouth; additive sedatives.Itch/sneezing after 1–2 days; sedation/renal considerations at first follow-up.
Loratadine / desloratadine (2nd-gen H1)Loratadine 10 mg PO daily; desloratadine 5 mg PO daily adult.Renal/hepatic impairment or interactions may require review; age-specific labeling.Headache, xerostomia, usually little sedation; possible CYP interactions with certain inhibitors.Assess nasal/ocular symptoms in 3–7 days and adverse effects.
Fexofenadine / bilastine / rupatadine (2nd-gen H1)Fexofenadine 60 mg PO BID or 120 mg daily (lecture); bilastine 20 mg daily on empty stomach; rupatadine 10 mg daily adult.Bilastine food/fruit juice reduce exposure; caution renal failure + P-gp inhibitors; rupatadine CYP3A4 inhibitors/grapefruit.Headache, occasional somnolence; fexofenadine separated from Al/Mg antacids by ≥2 h.Review effect by 3–7 days and medication timing/food effects.
Azelastine 137 mcg + fluticasone 50 mcg spray (Dymista; MACS)1 spray per nostril BID; daily during allergen exposure; step-up after insufficient INCS response.Nasal trauma, severe epistaxis; sedative use and CYP3A4 inhibitors.Bitter taste, epistaxis, occasional sedation; local irritation.Reassess 3–7 days; check bitterness technique and nosebleeds.
Olopatadine 665 mcg + mometasone 25 mcg spray (Ryaltris; MACS)2 sprays per nostril BID per lecture; product/age verification required.Avoid significant recent nasal trauma, severe epistaxis; age and pregnancy per monograph.Dysgeusia, epistaxis, headache; additive intranasal steroid effects.Reassess in 3–7 days; ongoing symptom score.
Ipratropium nasal (other Rx, verify indication/scope)0.03% nasal solution: often 2 sprays/nostril BID–TID for prominent watery rhinorrhea; does NOT reliably reduce congestion.Glaucoma or urinary retention caution; avoid spraying into eyes.Nasal dryness/bleeding; anticholinergic effects mostly local.Rhinorrhea in days; assess nasal dryness/bleeding.
Decongestants: oxymetazoline / pseudoephedrine (OTC)Oxymetazoline 0.05%, 1–2 sprays/nostril BID ≤3 days; pseudoephedrine adult 30–60 mg q4–6h PRN, max 240 mg/day; temporary rescue only.Avoid uncontrolled HTN, cardiovascular disease, glaucoma, recent MAOI; caution BPH/retention, pregnancy.Insomnia, hypertension, palpitations; rebound congestion with nasal decongestants >3 days.Check by 48–72 h; switch to INCS rather than prolonging decongestant.
Follow-up / monitoring: Symptom relief from H1 blockers within hours; INCS maximal in 3–14 days. Review at 3–7 days for adherence, spraying technique, nosebleeds and symptom severity; step up INCS → INCS+INAH if moderate/severe or persistent. Re-evaluate at 2–4 weeks.
Clinical pearl / evidence: Lecture algorithm: mild intermittent → 2nd-generation oral H1 (step up INCS); persistent or moderate/severe → INCS first, then combination INCS/intranasal H1. First-generation antihistamines generally NOT preferred.

21 | Pharyngitis / sore throat / confirmed GAS

OTC supportive · systemic antibiotics NOT BC MACSSource: HEENT 08 Pharyngitis, pages 10–35 + Canadian Paediatric Society/CDC guidance

Risk factors / etiology

School-age child (GAS peak 5–15 y), household/daycare contact, winter/spring, crowding; viral URI exposures. Immunocompromised or previous rheumatic fever can alter threshold for investigation.

Presentation / differential / complications

Viral clues: cough, coryza, hoarseness, conjunctivitis, oral ulcers, diarrhea. GAS clues: sudden severe sore throat, fever ≥38°C, tender anterior neck nodes, tonsillar exudate, absence of cough, palatal petechiae, scarlet-fever rash. Centor/McIsaac estimates need for testing, not a definitive diagnosis. Complications: abscess, otitis, rheumatic fever, post-streptococcal glomerulonephritis.

When to refer / scope limit

Emergency: drooling, stridor, respiratory distress, muffled/hot-potato voice, trismus, unilateral tonsillar swelling/uvular displacement, cannot swallow secretions, neck swelling, dehydration. Testing/physician visit for likely GAS, persistent/worsening ≥4–5 days, immunosuppression. Do not prescribe systemic antibiotics under BC MACS for pharyngitis.

Goals of therapy

Control painful swallowing and fever, maintain hydration/nutrition; for confirmed GAS, prevent rheumatic fever/complications and transmission.

Non-drug / counselling: Fluids, rest, salt-water gargle in capable older children/adults, soft food, warm/cool soothing fluids. No empiric antibiotics for clear viral presentation; use throat swab/RADT according to local pathway when GAS possible. Finish prescribed antibiotic course.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Acetaminophen / ibuprofen (OTC)Acetaminophen adult 500–1000 mg PO q6–8h PRN (max conservative 3000 mg/day); ibuprofen 200–400 mg q4–6h PRN (OTC max 1200 mg/day). Pediatric dosing by weight, separate guide/label.Ibuprofen avoid ulcer/GI bleed, CKD/dehydration, late pregnancy, NSAID allergy. Acetaminophen severe liver disease; watch combo cold products.GI upset, AKI/bleed (NSAIDs), hepatic toxicity from acetaminophen overdose; interactions anticoagulants and ACEI/diuretics.Reassess fever/pain after 24–48 h; fever >3 days or worsening refer.
Benzocaine/phenol topical throat products (OTC)Benzocaine lozenge or spray, phenol spray: dose per labelled formulation, brief pain relief ~30–45 min. Not a substitute for evaluation.Benzocaine: methemoglobinemia risk, avoid young children; lozenges choking hazard; avoid local anesthetic allergy.Numbness, hypersensitivity; rare cyanosis/methemoglobinemia (benzocaine).Monitor swallowing, numbness and breathing; stop urgently with blue/grey colour.
Penicillin V (confirmed GAS, other prescriber)Lecture: adults >27 kg 300 mg PO TID or 600 mg BID ×10 days. Current CDC option: adults 500 mg BID or 250 mg QID ×10 days. Verify local Canadian product strengths.Immediate penicillin allergy, severe prior beta-lactam reaction; renal adjustment if needed.Diarrhea, rash, anaphylaxis; consider interactions with warfarin and methotrexate.Symptoms should improve within 24–72 h; complete 10 days; refer if no improvement after 48–72 h.
Amoxicillin (confirmed GAS, other prescriber)Adults 500 mg PO BID ×10 days (lecture). Child 25 mg/kg/dose BID (max 500 mg/dose) or 50 mg/kg once daily (max 1 g/day) ×10 days per CDC.Penicillin allergy; suspected mononucleosis may provoke rash; renal impairment.Rash, nausea, diarrhea; anaphylaxis and C. difficile possible.Improvement in 48–72 h; monitor allergy and hydration.
Cephalexin (penicillin allergy NON-immediate only)Adults 500 mg PO BID ×10 days; child 20 mg/kg/dose BID (max 500 mg/dose) ×10 days.Avoid with immediate/anaphylactic penicillin hypersensitivity or cephalosporin allergy; renal adjust.Diarrhea/rash; warfarin can alter INR; C. difficile rare.Improvement in 48–72 h; allergy/diarrhea during course.
Clindamycin (severe penicillin allergy option)Adults 300 mg PO TID ×10 days; child 7 mg/kg/dose TID (max 300 mg/dose) ×10 days. Consider local resistance.Previous C. difficile/antibiotic-associated colitis, severe allergy.Diarrhea and high C. difficile risk; esophagitis if not taken with water.Urgent review for frequent watery/bloody diarrhea; symptoms by 48–72 h.
Clarithromycin (penicillin allergy alternative)Adults 250 mg PO BID ×10 days; child 7.5 mg/kg/dose BID (max 250 mg/dose) ×10 days.Prolonged QT, important CYP3A4 interacting drugs (e.g. statins, certain anticoagulants), severe hepatic issues.Dysgeusia, GI upset, QT prolongation; strong CYP3A4 inhibition.Check DDIs BEFORE dosing; review improvement at 48–72 h.
Azithromycin (penicillin allergy alternative)Lecture gives 500 mg PO daily ×3 days (adults), 20 mg/kg/day ×3 days pediatric; alternative guideline CDC: 500 mg day 1 then 250 mg daily days 2–5 adult. Choose local regimen, not both.QT prolongation, major macrolide allergy, resistant GAS prevalence.GI upset, QT prolongation; interactions with other QT-prolonging medicines.Reassess in 48–72 h and for recurrent symptoms after course.
Dexamethasone single dose (clinician-directed, NOT routine)Lecture mentions 10 mg PO once adults or 0.6 mg/kg PO once children; not routine recommendation.Diabetes, infection, GI bleeding, immunosuppression; risk–benefit needs clinician.Transient hyperglycemia, insomnia, agitation; additive effects with NSAIDs.Assess pain benefit over 24–48 h; not an alternative to appropriate diagnosis.
Follow-up / monitoring: Uncomplicated viral sore throat typically improves in 3–5 days. GAS: antibiotic recipients often start improving within 24–72 h; urgent referral for airway warnings, dehydration or unilateral worsening. Complete 10-day beta-lactam regimen. If positive GAS, stay home until afebrile and at least 12–24 h after starting appropriate antibiotic (local policy).
Clinical pearl / evidence: Lecture uses 3-day azithromycin while CDC guidance uses a 5-day schedule. These regimens differ; check Canadian local pathway, age/weight and susceptibility. Clinically suspected GAS requires confirmation rather than antibiotics based on score alone in most settings.

22 | Common cold / viral upper respiratory tract infection

OTC symptomatic · no BC MACS cold diagnosisSource: RESP 16 Cough and Cold, pages 8–24, 39–45

Risk factors / etiology

Frequent close contacts/daycare, crowded indoor exposure, tobacco smoke, poor sleep; children and immunocompromised may have more frequent or severe episodes.

Presentation / differential / complications

Viral URI (rhinovirus, coronavirus, RSV etc.): sore throat first, nasal rhinorrhea/congestion, sneezing, mild short fever, then cough that may persist up to 3 weeks. Normal course improves within 7–10 days. Purulent or coloured sputum alone is not proof of bacteria. Complications: secondary otitis/sinusitis, exacerbation of asthma/COPD, dehydration.

When to refer / scope limit

Emergency: difficulty breathing, cyanosis, chest pain, confusion, meningism, dehydration in infant. Medical review if fever >3 days, severe unilateral ear pain, high-risk immunocompromise, severe/worsening illness, cough >3 weeks or asthma/COPD deterioration; consider influenza/COVID if testing or treatment indicated.

Goals of therapy

Short-term comfort and sleep while illness self-resolves; avoid duplicate ingredients and unnecessary antibiotics.

Non-drug / counselling: Saline spray/rinse, sleep, fluids, smoke avoidance, humidification with maintained equipment, single-ingredient treatment by symptom. No OTC cough/cold combination products in children under 6; lecture recommends avoiding routine use through age 12. Prefer supportive strategies for pregnancy.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Acetaminophen for fever/pain (OTC)Adult 500–1000 mg PO q6–8h PRN, prudent OTC ceiling 3000 mg/day from all products; follow exact package ceiling and clinician advice.Advanced hepatic disease, chronic heavy alcohol use; avoid double-dosing in combination cold products.Liver toxicity with overdose; may raise INR if repeated higher doses with warfarin.Fever and comfort over 24–48 h; fever continuing >3 days merits referral.
Ibuprofen for pain/fever (OTC)Adult 200–400 mg PO q4–6h PRN with food; OTC max 1200 mg/day; shortest course.NSAID allergy, GI bleeding/ulcer, advanced CKD, significant dehydration, late pregnancy.Dyspepsia/bleeding, renal injury, edema; interactions anticoagulants, ACEI/ARB plus diuretic, SSRIs.Pain/fever and GI/renal tolerance over first 2–3 days.
Oxymetazoline topical decongestant (OTC)0.05% adult 1–2 sprays/nostril q12h as needed for congestion; ≤3 days.Glaucoma, uncontrolled HTN, CAD, MAOIs; age-specific label and pregnancy considerations.Rebound rhinitis, dry nose, sympathomimetic effects.Check at 48–72 h and STOP by day 3.
Pseudoephedrine oral decongestant (OTC)30–60 mg PO q4–6h adult PRN, max 240 mg/day; only brief use for congestion.Uncontrolled HTN, cardiac arrhythmia, coronary disease, MAOI, urinary retention/BPH, narrow-angle glaucoma.Palpitations, nervousness, insomnia, elevated BP; stimulant interactions.Reassess benefit/HR/BP and insomnia within 1–2 days.
Ipratropium nasal 0.03% (Rx outside cold MACS)Common rhinorrhea regimen: 2 sprays/nostril BID–TID for short period; does not improve obstructive congestion.Anticholinergic-sensitive glaucoma/retention; avoid eyes.Local dryness/epistaxis; low systemic exposure.Monitor watery nasal drainage over 2–3 days.
Diphenhydramine 25–50 mg (OTC; generally avoid for URI)Adult often 25–50 mg PO q4–6h (max product label); not routinely recommended for viral cold due to marginal benefit/anticholinergic burden.Older adults, glaucoma, urinary retention, sedatives, driving, young children.Drowsiness, confusion, xerostomia, falls; additive anticholinergics/alcohol.Reconsider after first dose; avoid routine ongoing use.
Oral phenylephrine (OTC in some combos)Common labelled adult 10 mg PO q4h, but oral efficacy for congestion is not established; prefer other options.Cardiovascular disease, HTN, MAOI; check product label.Insomnia, BP increase; stimulant interaction.Avoid ineffective combination products; reassess within 1–2 days.
Follow-up / monitoring: Symptom check within 48–72 h. Typical improvement 7–10 days; residual cough may last 2–3 weeks. Fever >3 days, recurrent fever after improvement, new breathlessness or focal symptoms ⇒ reassess. No routine antibiotic treatment.
Clinical pearl / evidence: Use one single-ingredient agent per predominant symptom. The lecture explicitly recommends avoiding OTC cough/cold products in young children and highlights overdose risk from multi-ingredient formulations.

23 | Cough: dry, productive, postviral and red flags

OTC symptom management · no standalone BC MACS cough diagnosisSource: RESP 16 Cough and Cold, pages 15–45

Risk factors / etiology

Postviral airway irritation, smoking/vaping, asthma/COPD, GERD, postnasal drainage; ACE inhibitors and environmental irritants. High-risk context: heart failure, immunosuppression, TB exposure.

Presentation / differential / complications

Dry: tickling nonproductive cough (often worse at night); productive: sputum with possible viral URI; postinfectious may last 3–8 weeks (needs workup depending on pattern). Complications: sleep disturbance, dehydration, musculoskeletal pain; a “wet cough” with dyspnea may be pneumonia or COPD exacerbation.

When to refer / scope limit

Urgent: hypoxia, marked dyspnea, hemoptysis, chest pain, confusion, suspected pneumonia, severe asthma/COPD exacerbation. Assessment for cough >3 weeks, persistent fever, recurrent/worsening illness, significant risk factors, weight loss/night sweats. ACE inhibitor cough merits medication review; do not suppress symptoms of COPD exacerbation.

Goals of therapy

Soothe throat and improve sleep; limit treatment to short symptom-directed trials while treating or investigating cause.

Non-drug / counselling: Honey 2.5–5 mL before bedtime (age ≥1 year only); warm drinks, hydration, avoid smoke, nasal saline if postnasal drip. Honey <1 y carries infant botulism risk; hard lozenges choking hazard. Evidence for OTC cough preparations is limited.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Dextromethorphan (DM; OTC) for disruptive dry coughAdult immediate-release 10–20 mg PO q4h or 30 mg q6–8h; max 120 mg/day (all products). Prefer bedtime-only if occasional symptoms.Avoid MAOI (including linezolid/methylene blue) within 14 days, strong serotonergic co-medications, severe respiratory illness requiring evaluation; check age/product.Dizziness, drowsiness, nausea; serotonin syndrome with SSRI/SNRI/MAOI or CYP2D6 inhibitors increasing exposure; abuse potential.Judge benefit by 1–3 nights; stop if no benefit or serotonin toxicity symptoms.
Guaifenesin (OTC) for bothersome thick sputumAdult IR 200–400 mg PO q4h as needed (max 2400 mg/day); ER 600–1200 mg PO q12h (max 2400 mg/day), with fluids.Persistent purulent sputum plus fever/dyspnea needs evaluation; do not mask pneumonia/COPD flare.Nausea, dizziness; few major interactions; limited evidence for meaningful improvement.Trial 2–3 days; review sputum, cough function and new red flags.
Honey (non-drug)Age ≥1 year: 2.5–5 mL (½–1 tsp) at bedtime for troublesome cough, as desired; dental hygiene.Absolute avoid in infants <12 months; sugar considerations in diabetes.Usually mild GI effects; no drug interaction expected.Benefit overnight; discontinue if no relief.
Diphenhydramine / doxylamine (OTC night products)Not first-line antitussives; doses depend on age/product; avoid simply to induce sleep. Many combo preparations contain analgesic + antitussive.Older adults, glaucoma, retention, alcohol/sedatives, fall risk; avoid paediatric cough/cold products under 6.Daytime sedation, anticholinergic effects, falls/delirium; additive CNS depressants.Review first dose; stop with confusion, severe sedation or poor function.
Inhaled bronchodilator or controller (prescription)Not an OTC cough remedy. Wheezing/dyspnea in known asthma/COPD → review action plan and prescribed inhalers; new symptoms require assessment.No diagnosis of asthma/COPD solely from a cough complaint.Tremor/tachycardia with short-acting beta-agonist; steroids may cause thrush with inappropriate technique.Reassess airway symptoms promptly; escalating reliever need requires medical review.
Follow-up / monitoring: Assess symptom trend after 48–72 h of cough remedy; investigate if worsening or prolonged >3 weeks. Review prescribed therapies/ACE inhibitor, inhaler technique, comorbid asthma/COPD. Document lack of evidence and stop ineffective suppressants.
Clinical pearl / evidence: Lecture case: new coloured sputum and worsening cough in a COPD patient was treated as possible acute exacerbation requiring clinician assessment, not OTC guaifenesin alone.

24 | Conjunctivitis: bacterial, viral and allergic

BC MACS: ophthalmic drugs for allergic, bacterial or viral conjunctivitisSource: HEENT 15 Conjunctivitis, pages 7–65

Risk factors / etiology

Close contacts with red eye, recent URI, daycare, shared cosmetics/towels, contact lenses/poor lens hygiene; allergic rhinitis/seasonal exposures, eczema; HSV exposure/immunocompromise increase risk.

Presentation / differential / complications

Bacterial: diffuse redness, mucopurulent discharge and stuck eyelids, often mild irritation; viral: watery discharge, URI, preauricular nodes, often unilateral then bilateral; allergic: dominant itch, bilateral watery/stringy discharge, seasonal triggers. Complications: keratitis/corneal ulcer, scarring, significant vision loss (rare), hyperacute gonococcal infection.

When to refer / scope limit

Same-day urgent eye evaluation: contact lens wearer with red painful eye, photophobia, visual loss, significant pain, corneal opacity, ciliary flush, abnormal pupil, ocular HSV/zoster, injury/chemical exposure, severe purulence, neonate, suspected gonococcal disease. Also refer recurrent/chronic >4 weeks or nonresponse at 48 h. Do not treat potential corneal ulcer as simple MACS conjunctivitis.

Goals of therapy

Preserve vision, relieve discomfort/discharge, manage allergic triggers, prevent transmission; use antibiotics only when bacterial infection is likely/appropriate.

Non-drug / counselling: Wash hands, avoid rubbing eyes and shared towels, remove/discard suspect cosmetics, stop contact lenses until fully recovered. Cold compress for allergy/viral; warm gentle cleaning for crusted bacterial lids. If multiple drops, space ≥5 min; drops before ointment; no tip contact with eye.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Polymyxin B/gramicidin/bacitracin combinations (OTC ophthalmic; product dependent)Polysporin Eye/Ear drops: label may direct 1–2 drops in affected eye up to 4–6 times/day; lecture gives initial frequent 1–3 drops then taper. Ophthalmic ointment 2–5 times/day; verify actual DIN and indication.Bacitracin/polymyxin allergy; avoid contact lenses and corneal ulcers; ensure ophthalmic formulation.Transient stinging, contact allergy; no major systemic DDIs.Reassess discharge and pain in 24–48 h; worsening triggers referral.
Polymyxin B + trimethoprim (ophthalmic Rx/MACS if Schedule I)Typical 10,000 units/mL + 1 mg/mL drops: lecture titrates 1–3 drops initially at frequent intervals then 1–2 drops 4–6×/day; actual product label governs duration.Known allergy to either component, corneal disease/trauma, contact lens-associated red eye.Stinging, eyelid swelling/contact dermatitis; minimal systemic DDIs.Expect improving discharge in 48 h; urgent referral if photophobia or vision change.
Fusidic acid 1% viscous ophthalmic drops (Fucithalmic; Rx/MACS)1 drop affected eye BID ×7 days per lecture/label; verify local product availability.Hypersensitivity, ocular keratitis or uncertain diagnosis.Transient burning, blurred vision, local allergy; low systemic DDIs.Reassess day 2; complete course if prescribed, refer if no improvement.
Erythromycin 0.5% ophthalmic ointment (Rx/MACS)Lecture: apply small ribbon to affected conjunctival sac 2–6 times/day; duration per product/clinical assessment (usually ~5–7 days).Macrolide allergy; do not use topical skin formulations in eye.Blurred vision after application, mild burning, allergy; minimal systemic interactions.Improve within 48–72 h; persistent photophobia or discharge refer.
Tobramycin 0.3% ophthalmic (Rx/MACS; selected bacterial cases)1–2 drops q4h for bacterial infection (lecture); ophthalmic ointment BID–TID. Duration depends on label/clinical response.Aminoglycoside allergy; reserve after adequate red-eye assessment; pediatric dosing depends on age/product.Stinging, hypersensitivity; prolonged use may select resistant organisms.Reassess after 48 h; do not escalate with worsening pain or vision changes.
Ciprofloxacin 0.3% ophthalmic (Rx/MACS; specialist for keratitis)Lecture bacterial conjunctivitis: 1–2 drops q2h while awake ×2 days, then 2 drops q4h while awake ×5 days; avoid routine use for uncomplicated watery eye.Contact lens-associated keratitis requires urgent assessment; quinolone allergy.Bitter taste, eye irritation, precipitation/white deposits; minimal systemic DDIs.24–48 h reassessment; refer immediately if photophobia, corneal spot or pain.
Ofloxacin 0.3% / moxifloxacin 0.5% (Rx/MACS)Ofloxacin 1–2 drops q2–4h ×2 days then QID ×5 days (lecture); moxifloxacin 1 drop TID ×7 days (lecture). Verify monographs.Quinolone allergy; avoid empiric use with unexplained visual change or painful contact lens eye.Transient stinging, dysgeusia, rare hypersensitivity; low systemic exposure.Clinical review at 48 h; referral if not improving.
Gatifloxacin ophthalmic (Rx/MACS if marketed)Lecture: 1 drop q2h while awake up to 8×/day ×2 days, then 1 drop QID; check exact strength/formulation/DIN and duration.Fluoroquinolone allergy; reserve for justified bacterial indication.Burning, taste disturbance, conjunctival hyperemia.Reassess within 48 h; check ocular pain/vision.
Ketotifen ophthalmic (OTC antihistamine)0.025%: 1 drop affected eye q8–12h (most labels BID), during exposure/while symptomatic.Contact lens caution; do not instill over soft contacts; allergy to components.Transient stinging, headache; negligible systemic DDIs.Itch relief typically same day; reassess at 48–72 h.
Olopatadine ophthalmic (OTC/Rx depending product)0.1%: generally 1 drop each affected eye BID at 6–8 h intervals; 0.2% often once daily; follow strength-specific DIN.Ocular infection/keratitis must be distinguished; contact lens restrictions per label.Transient discomfort, headache, mild blurred vision; minimal DDIs.Itch and tearing in 1–3 days; refer if no improvement at 1 week.
Sodium cromoglycate (cromolyn) ophthalmic (OTC mast-cell stabilizer)2% drops: lecture 1–2 drops 4–6 times/day regularly during allergen exposure; onset slower (days–weeks).Not for rapid relief of severe eye pain or an untreated infection.Stinging, burning; minimal systemic interactions.Review regular adherence/effect in 1–2 weeks; not immediate rescue.
Naphazoline + pheniramine/antazoline drops (OTC, short term)Combination allergy/redness drops: 1–2 drops up to QID by product; limit short-term use.Glaucoma, severe HTN/cardiovascular disease, MAOI; caution young children and contact lens.Rebound redness, dryness, tachycardia if systemic absorption; avoid chronic use.Stop after a few days; refer if persistent redness.
Artificial tears (OTC)Carboxymethylcellulose 0.5–1% / hypromellose / polyvinyl alcohol: 1–2 drops TID–QID or PRN per product; preservative-free if frequent use.Hypersensitivity, avoid contaminated bottles; severe pain/visual change is not dry eye.Brief blur/stinging; benzalkonium chloride can irritate with frequent use.Comfort within minutes; review 48–72 h and ongoing triggers.
Follow-up / monitoring: Mild bacterial cases may self-resolve over 7–10 days; viral often 1–2 weeks; allergic improvement within hours–days using antihistamines. Review all red eyes at 24–48 h if treated as bacterial. Immediate assessment for corneal symptoms or deterioration.
Clinical pearl / evidence: BC MACS does include conjunctivitis. However the underlying presentation must be low risk and confidently distinguished from keratitis, glaucoma, uveitis, HSV or trauma. The lecture lists several antibiotics; not every agent is preferred for an uncomplicated case.

25 | Blepharitis: anterior vs posterior (meibomian)

OTC lid hygiene · prescription therapy outside standalone BC MACSSource: HEENT 16 Blepharitis & Eyelid Disorders, pages 4–13

Risk factors / etiology

Seborrheic dermatitis, rosacea, Demodex infestation, altered meibomian secretion, Staphylococcus colonization, contact lenses, smoking, dry eye, chronic recurrent disease.

Presentation / differential / complications

Anterior: irritation/erythema/crusts and collarettes around eyelashes; staphylococcal harder crusts, seborrheic greasy scale. Posterior: meibomian gland dysfunction, foamy/oily tears, thick secretions, burning, recurrent dry eye. Usually chronic bilateral. Complications: recurrent hordeola/chalazia, keratoconjunctivitis, corneal irritation.

When to refer / scope limit

Pain beyond mild irritation, vision change, photophobia, corneal opacity, marked unilateral swelling/cellulitis; persistent or severe disease not responding to 1–2 weeks of lid care. Blepharitis is not a separate BC MACS condition; select treatments only within actual applicable diagnosis and scope.

Goals of therapy

Break chronic inflammation/crusting cycle, restore meibomian secretion, protect tear film, reduce recurrence and antibiotic overuse.

Non-drug / counselling: Warm compress 5–10 min 1–2×/day, gentle lid-margin massage and cleaning with commercial eyelid wipes/diluted cleanser if tolerated; artificial tears if symptomatic. Avoid eye makeup during flares; clean reusable tools, avoid rubbing.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Warm compress + lid hygiene (non-drug FIRST LINE)Warm compress 5–10 min, gentle massage, lid-margin cleansing daily; continue maintenance after improvement.Avoid scalding water, vigorous rubbing with eye pain/trauma.Overly aggressive scrubbing may worsen irritation; no DDIs.Review crusting/itch over 1–2 weeks; continue maintenance.
Erythromycin 0.5% ophthalmic ointment (other authorized prescriber)Lecture anterior blepharitis: thin ribbon to eyelid margin at bedtime ×1–2 weeks if significant bacterial component and lid hygiene insufficient.Macrolide allergy, uncertain diagnosis; do not put dermatologic erythromycin formulation into eye.Transient blur, burning/contact dermatitis; low systemic DDIs.Evaluate lid inflammation at 7–14 days; stop if allergy.
Fusidic acid 1% ophthalmic viscous drops (other prescriber)Lecture: 1–2 drops q12h ×1–2 weeks in anterior blepharitis if selected.Drug allergy; uncertain bacterial indication; product availability.Instillation discomfort/blur; negligible DDIs.Monitor lid crusting at 1 week.
Doxycycline / minocycline (clinician-directed posterior refractory)Lecture: doxycycline 100 mg PO daily or minocycline 50–100 mg PO daily, generally 2–4 weeks for moderate–severe or refractory posterior blepharitis (not first line).Pregnancy, children below recommended age, tetracycline allergy; check photosensitivity/esophageal disease.GI upset, photosensitivity, esophagitis; separate from iron/calcium/antacids, warfarin INR caution.Response and tolerance after 1–2 weeks; assess need beyond 2–4 weeks.
Tetracycline oral (clinician-directed alternative)Lecture 250 mg PO QID for 2–4 weeks when indicated; less convenient than doxycycline.Pregnancy, younger children, impaired renal function, allergy; esophagitis.GI intolerance/photosensitivity; chelation with divalent/trivalent cations.Response in 2–4 weeks; persistent severe disease warrants specialist review.
Preservative-free artificial tears (OTC adjunct)1–2 drops per eye TID–QID or PRN if dry eye; use lipid-containing products if evaporative symptoms.Significant red painful eye/blurred vision must be referred.Mild transient blur; no systemic DDIs.Comfort within days and tear-film symptoms 1–2 weeks.
Follow-up / monitoring: Check response to hygiene after 1–2 weeks (a chronic maintenance program is common). For oral tetracyclines, monitor GI effects, photosensitivity, pregnancy status and efficacy by 2–4 weeks. Refer recurrent severe ocular surface disease.
Clinical pearl / evidence: Antibiotics do not replace mechanical lid hygiene. Treat associated rosacea, seborrheic dermatitis and dry eye when applicable; do not label blepharitis alone as MACS conjunctivitis.

26 | Hordeolum (stye) and chalazion

OTC conservative care · NOT separate BC MACS prescribing diagnosisSource: HEENT 16 Blepharitis & Eyelid Disorders, pages 14–22

Risk factors / etiology

Chronic blepharitis, meibomian gland dysfunction/rosacea, cosmetic contamination, rubbing eyes, recurrent bacterial colonization.

Presentation / differential / complications

Hordeolum: acute tender localized red nodule of eyelid, external near lash follicle or internal tarsal gland; may drain. Chalazion: gradual, typically minimally painful sterile firm eyelid nodule from blocked meibomian gland. Complications: preseptal cellulitis, visual disturbance if large, rare recurrent lesion mimicking malignancy.

When to refer / scope limit

Same day: spreading erythema/fever, proptosis, impaired eye movement, pain with movement, visual change, photophobia, suspected orbital cellulitis. Routine referral if external hordeolum not improving in 2–3 days, internal within ~1 week, chalazion persists or recurs in same site (exclude malignancy).

Goals of therapy

Promote drainage and resolution, reduce pain/swelling, avoid unnecessary antibiotics or manipulation.

Non-drug / counselling: Warm (not hot) compress 10–15 minutes, 3–4 times/day for 1–2 weeks; gentle massage/eyelid cleansing after warmth; do not squeeze/lance at home. Stop makeup/contact lenses temporarily.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Warm compress/massage (FIRST LINE)10–15 min per session, 3–4×/day; continue until resolved or reviewed (usually 1–2 weeks).Avoid scalding the skin, aggressive pressure, home incision; urgent referral for orbital signs.Temporary redness; no DDIs.External stye review at 2–3 days; internal stye by 1 week; chalazion 1–2 weeks.
Acetaminophen (OTC) if painAdults 500–1000 mg PO q6–8h PRN, prudent max 3000 mg/day; 1–3 days only.Liver disease, combination-product overdose.Nausea/rare rash, hepatotoxicity at excessive doses.Pain in 24–48 h; worsening pain warrants assessment.
Erythromycin 0.5% ophthalmic ointment (clinician-directed)Not routine for uncomplicated chalazion/stye. Used when clinician identifies secondary infection or after incision (per lecture), dosing per procedure/label.Allergy, do not use automatically for a sterile chalazion.Temporary blurred vision, burning, allergy.Reassessment after procedure or within 48 h if infection.
Systemic antibiotic / incision & drainage (clinician only)Not indicated for simple isolated stye/chalazion; considered for spreading cellulitis or persistent lesion needing surgical drainage.Never delay urgent assessment for orbital cellulitis signs.Antibiotic-specific adverse effects and resistance; procedural risks.Same-day clinician follow-up if spreading infection/visual symptoms.
Follow-up / monitoring: External hordeolum may begin to drain within 2–3 days of compresses; internal hordeolum by ~1 week. Chalazion may require weeks to resolve; refer persistent/enlarging lesions, recurrent same-location nodules, pain or any visual changes.
Clinical pearl / evidence: Distinguish acute painful stye from slower sterile chalazion. Routine antimicrobial prescribing for chalazion is inappropriate.

27 | Dry eye disease: episodic vs chronic

OTC lubricants · Rx specialist drugs NOT BC dry-eye MACSSource: HEENT 16 Dry Eye, pages 35–80

Risk factors / etiology

Age, female sex/hormonal changes, contact lenses, prolonged screen use/reduced blink, smoking, air drafts, meibomian gland dysfunction/rosacea, Sjögren syndrome. Drug triggers: antihistamines, anticholinergics, oral decongestants, isotretinoin, diuretics, antidepressants.

Presentation / differential / complications

Tear-film instability, deficiency or excess evaporation → grittiness, burning, fluctuating blur, paradoxical watering, contact-lens discomfort, red irritated eyes; often worsens at end of day/screen use. Complications: corneal epithelial injury/keratitis, persistent pain and vision disturbance.

When to refer / scope limit

Urgent: true pain, photophobia, persistent blurred vision, corneal opacity, chemical injury, contact lens-related red eye, unusual unilateral discharge. Refer if persistent >5 days despite appropriate self-care, recurrent/chronic moderate–severe symptoms, suspected Sjögren (dry mouth + eyes), systemic disease, marked corneal signs.

Goals of therapy

Restore ocular comfort and stable tear film, reduce inflammation/evaporation and epithelial injury, preserve vision/function, minimize preservative toxicity.

Non-drug / counselling: 20-20-20 screen breaks, deliberate blinking, adjust screen below eye level, reduce air drafts, smoke avoidance, lid warm compress/hygiene if meibomian disease. Choose preservative-free tears with frequent use or contact lens issues; day drops, night gel/ointment if needed. Do not use vasoconstrictor “get the red out” drops chronically.
Drug / category / scopeStrength • dose • frequency • durationContraindications / avoid / precautionsAdverse effects / important interactionsMonitoring and timing
Carboxymethylcellulose sodium (CMC) artificial tears (OTC)0.5% or 1% (Refresh/Celluvisc examples): 1–2 drops affected eye TID–QID or as needed; may use preservative-free more frequently.Avoid using contaminated multidose bottles; significant pain/photophobia needs referral.Brief blur, stickiness, mild burning; few DDIs.Comfort within minutes; reassess 3–5 days, and frequency/BAK exposure.
Hypromellose / hydroxypropyl methylcellulose (OTC)0.3% examples: 1–2 drops 3–4×/day or PRN; some gels longer duration.Allergy and contamination; protect bottle tip.More viscous options can blur vision and crust lashes.Within minutes; check blur/tolerance at 3–5 days.
Polyvinyl alcohol / povidone (OTC)PVA 1.4% or povidone ~1.25% per product: 1–2 drops 3–4×/day or PRN.Avoid if preservative irritation; select PF for frequent dosing.Transient stinging, blur.Monitor comfort and total daily instillations over first week.
PEG 400 / propylene glycol / glycerin combinations (OTC)E.g., PEG 400 0.4% + propylene glycol 0.3% (Systane type); 1–2 drops PRN up to several times/day according to product.Ingredient-specific sensitivity; if severe painful red eye, refer.Temporary blur/tingling; few DDIs.Relief in minutes; evaluate persistent symptoms after 3–5 days.
Sodium hyaluronate 0.15% and lipid-enhanced drops (OTC)Hyaluronate 0.15% examples: 1–2 drops PRN (often 3–6×/day); consider lipid-based drops for evaporative dryness.Allergy, product compatibility with soft contacts per label.Rare irritation, brief blur.Review 3–7 days; match formulation to aqueous vs evaporative symptoms.
Night-time ocular gel/ointment (OTC)Carbomer 0.2% gel or petrolatum/mineral oil ophthalmic ointment: small ribbon at bedtime if nighttime symptoms; follow exact ocular product directions.Lanolin allergy in some ointments; do not use skin ointment in eye.Long-lasting blurred vision, greasy lids; caution driving until vision clear.Next-morning comfort within 3–5 days.
Cyclosporine 0.05% ophthalmic (Restasis, Rx outside MACS)1 drop each eye BID ongoing for chronic moderate–severe disease under clinician; response can take 3 weeks–3 months.Active untreated ocular infection, drug allergy; separate other drops ≥15 min per product instructions.Burning/stinging common; rare hypersensitivity; no meaningful systemic interactions.Assess stinging during first 2 weeks; efficacy at 6–12 weeks.
Cyclosporine 0.09% ophthalmic (Cequa, Rx outside MACS)1 drop each eye BID ongoing under optometrist/ophthalmologist; not proven clearly superior to 0.05%.Severe untreated eye infection, drug allergy; product instructions for contacts.Instillation pain, conjunctival hyperemia; few systemic interactions.Assess tolerability in 1–2 weeks; response 6–12 weeks.
Lifitegrast 5% ophthalmic (Xiidra, Rx outside MACS)1 drop each eye BID for chronic inflammatory dry eye; benefit may begin ~2 weeks, can take months.Allergy, active unresolved infection/other serious eye disease; contacts removed per label.Dysgeusia, eye irritation, transient blur; few systemic interactions.Check early dysgeusia/comfort at 2 weeks; efficacy over 6–12 weeks.
Topical loteprednol ophthalmic (specialist-directed only)Short-term ocular steroid course may precede cyclosporine in specialist regimens; no general OTC dose recommended.Herpetic keratitis, fungal infection, increased IOP/glaucoma; requires slit-lamp/IOP monitoring.Infection masking, ocular hypertension, cataract with prolonged use.IOP and cornea monitored by eye-care specialist; not MACS dry-eye treatment.
Follow-up / monitoring: Mild episodic dry eye should improve within minutes of lubricants and trend better within 3–5 days. If dosing >4 times/day or chronically, use preservative-free drops. Refer chronic/recurrent disease for ocular examination; cyclosporine/lifitegrast require 6–12-week assessment and specialist follow-up.
Clinical pearl / evidence: Studies do not establish a single superior lubricant for everyone. Preservative benzalkonium chloride (BAK) can worsen ocular-surface irritation with frequent exposure; the lecture advises avoiding BAK if dosing often or using several ocular products.

Sources, boundaries and verification

Lecture sources provided by user: GI 14 Oral Care (77 slides, Oct 2026), GI 09 Abdominal Gas (20 slides, Oct 2024), GI 11 GERD/Dyspepsia (69 slides, Oct 2026), GI 07 Nausea/Vomiting (62 slides, Oct 2026), GI 05 Constipation (54 slides, Oct 2026), GI 04 Diarrhea (28 slides, 2026). See page ranges noted at every chapter. Content is condensed and paraphrased; illustrative dosing is not exhaustive for every marketed formulation. Also used user-provided Acne.pdf (CPhA, 2022), HEENT 06 Sinusitis, HEENT 07 Allergic Rhinitis, HEENT 08 Pharyngitis, RESP 16 Cough and Cold, HEENT 15 Conjunctivitis, and HEENT 16 Blepharitis/Eyelid Disorders/Dry Eye.

Scope: BC Ministry of Health: Minor Ailments and Contraception Service and College: medication class limits. Schedule I medication must be in the permitted drug category for each listed ailment; the regulator does not supply a closed drug-by-drug list.

Selected verification: Health Canada dimenhydrinate labelling standard (adult/pediatric motion-sickness doses); Health Canada ranitidine NDMA restrictions and DIN status (some marketed, others cancelled); Canadian Transderm-V discontinuation notice; Health Canada Pepto-Bismol 262-mg product listing.

Important scope limitations: BC MACS prescribing assumes a low-risk minor presentation, confirmed within the pharmacist's competence without tests and short-term/episodic treatment. A drug listed as a specialist medication here does NOT thereby become independently prescribable for constipation, diarrhea or nausea. Hospital IV PONV dosing is not an outpatient counselling dose. Paediatric/renal/pregnancy regimens and prescriptions must be individualized; not all possible Canadian dosage forms/strengths are represented.

Additional clinical cross-checks (outside supplied lectures): CDC Group A Strep 2025 and Canadian Paediatric Society GAS statement (confirmation and dosing); Health Canada cough-and-cold medication risks in children; AAO 2026 contact lens infection risks. Drug strengths and availability vary by Canadian product; US doses are NOT automatically Canadian monograph directions.

Added lectures: MSK 07: Topical OTC Analgesics (2025), IID 16: UTI (Jan 2025), DERM 04/05: Lice & Scabies (2025), DERM 09: Rosacea (2025), DERM 12: Onychomycosis (2024), DERM 13: Atopic & Contact Dermatitis (2025). Page numbers in each section refer to those original sources.

Official BC MACS: College of Pharmacists of BC pharmacist-prescribing scope; BC Ministry of Health MACS conditions and drug classes; BC Pharmacy Association MACS drug categories. BCPhA Drug Products for Minor Ailments and Contraception list updated Mar 23, 2026 (non-exhaustive).

Known limits: Medication regimens given are adult teaching examples; high-risk populations, formulation-specific strengths, DINs, pregnancy/breastfeeding and renal function require current Canadian reference checking. Specialist-directed medications are shown for contrast and are not independently prescribable under a topical-only drug category. Older lecturer comments, prescribing status and drug availability may have changed.